



R **RESEARCH OPPORTUNITIES** **ALERT**

Issue 33: Volume 1b



GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH)

(Quarter: October – December, 2018)

A Compilation by the

PRE- & POST AWARD SERVICES
OFFICE OF RESEARCH, INNOVATION AND DEVELOPMENT (ORID)
UNIVERSITY OF GHANA

SEPTEMBER 2018

Research Grants

Innovation Grants

Academic-Industry Grants

Collaborative Opportunities

Technology Development Grants



TABLE OF CONTENT

Serious adverse drug reaction research (R21)	22
Serious adverse drug reaction research (R01)	22
Novel genomic technology development (R01 clinical trial not allowed)	22
Novel genomic technology development (R21 clinical trial not allowed)	22
Human Heredity and Health in Africa consortium biorepository (U24 clinical trial not allowed)	23
NCCIH mind and body clinical trial cooperative agreement (U01)	23
BRAIN Initiative – tools to target, identify and characterise non-neuronal cells in the brain (R01– clinical trial not allowed)	23
BRAIN initiative – biology and biophysics of neural stimulation (R01 clinical trial optional)	23
Immune mechanisms at the maternal-foetal interface (R01 clinical trial optional)	24
Dissemination and implementation research in health (R01 clinical trial optional)	24
The health of sexual and gender minority populations (R01 clinical trial optional)	24
Prescription drug abuse (R01 clinical trial optional)	25
Diet and physical activity assessment methodology (R01 clinical trial not allowed)	25
International research collaboration on drug abuse and addiction research (R01 clinical trial optional)	25
Bioengineering research grants (R01 clinical trial optional)	26
Behavioural and integrative treatment development programme (R01 clinical trial optional)	26
Modelling of infectious disease agent study research projects (R01)	26
Women and sex or gender differences in drug and alcohol abuse or dependence (R01 clinical trial optional)	27
Advancing erythroid cell biology (R01)	27
Ethical, legal and social implications of genomic research regular research programme (R01)	27
Ancillary studies to major ongoing clinical research studies to advance areas of scientific interest within the mission of the NIDDK (R01 clinical trial optional)	27
Addressing health disparities in NIDDK diseases (R01 clinical trial not allowed)	28
Mechanisms, models, measurement and management in pain research (R01 clinical trial optional)	28
Research project grant (parent R01 clinical trial required)	28
Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R01)	28
Nutrition and alcohol-related health outcomes (R01)	29
Screening and brief alcohol interventions in underage and young adult populations (R01 clinical trial optional)	29
Health promotion among racial and ethnic minority males (R01 clinical trial optional)	29



Public policy effects on alcohol-, marijuana, and other substance-related behaviours and outcomes (R01)	29
Epidemiology and prevention in alcohol research (R01 clinical trial optional)	30
Programme for extramural or intramural alcohol research collaborations (U01 clinical trial optional)	30
Genetic susceptibility and variability of human structural birth defects (R01).....	30
NLM research grants in biomedical informatics and data science (R01 clinical trial optional)	30
Investigations on primary immunodeficiency diseases/inborn errors of immunity (R01 clinical trial not allowed).....	31
Methodology and measurement in the behavioural and social sciences (R01 clinical trial optional)	31
Research to advance vaccine safety (R01 clinical trial not allowed)	31
Secondary analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R01).....	31
Drug discovery for nervous system disorders (R01)	32
Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional)	32
Obesity policy evaluation research (R01)	32
Selected topics in transfusion medicine (R01 clinical trial optional)	32
Stimulating haematology investigation – new endeavours (R01)	33
Alzheimer’s drug development programme (U01 clinical trial optional).....	33
Advances in polycystic kidney disease (R01)	33
Multidisciplinary research in vulvodynia (R01 clinical trial optional)	33
Research on autism spectrum disorders (R01 clinical trial optional).....	34
Mechanisms of alcohol-associated cancers (R01)	34
Natural history of disorders identifiable by screening of newborns (R01 clinical trial optional)	34
NINDS exploratory clinical trials (U01 clinical trial required).....	34
NINDS efficacy clinical trials (U01 clinical trial required)	35
Novel biomarkers for the development of HIV incidence assays with improved specificity (R01 clinical trial optional).....	35
Hearing health care for adults – improving access and affordability (R01 clinical trial optional)	35
Preclinical research on model organisms to predict treatment outcomes for disorders associated with intellectual and developmental disabilities (R01).....	35
Outcome measures for use in treatment trials for individuals with intellectual and developmental disabilities (R01 clinical trial optional)	36
Ancillary studies to the NIDDK intestinal stem cell consortium (R01).....	36
Obesity and asthma – awareness and self-management (R01 clinical trial optional).....	36
Cellular and molecular biology of complex brain disorders (R01).....	36



Development of appropriate paediatric formulations and paediatric drug delivery systems (R01)	37
Advancing basic neurobiology toward translation through assay development (R01 clinical trial not allowed).....	37
Healthy habits – timing for developing sustainable healthy behaviours in children and adolescents (R01 clinical trial optional)	37
mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01 clinical trial optional)	37
NeuroNEXT clinical trials (U01 clinical trial optional)	38
Mechanisms mediating osteoarthritis in ageing (R01).....	38
Discovery of in vivo chemical probes for novel brain targets (R01).....	38
Maternal nutrition and pre-pregnancy obesity – effects on mothers, infants and children (R01 clinical trial optional)	38
Environmental exposures and health: exploration of non-traditional settings (R01 clinical trial optional).....	39
Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional)	39
Juvenile protective factors and their effects on ageing (R01).....	39
Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R01 clinical trial optional).....	39
Examination of survivorship care planning efficacy and impact (R01 clinical trial optional)	40
Effects of in utero alcohol exposure on adult health and disease (R01 clinical trial optional)	40
Improvement of animal models for stem-cell-based regenerative medicine (R01).....	40
Research on comparative effectiveness and implementation of HIV/AIDS and alcohol interventions (R01 clinical trial optional).....	40
Biomarkers for diabetes, digestive, kidney and urologic diseases using biosamples from the NIDDK repository (R01)	41
Research grants using the resources from the osteoarthritis initiative (R01 clinical trial not allowed)	41
Advancing the science of geriatric palliative care (R01 clinical trial optional)	41
Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01 clinical trial optional)	41
Family-centred self-management of chronic conditions (R01 clinical trial optional).....	42
Alcohol-induced effects on tissue injury and repair (R01)	42
Community partnerships to advance research (R01 clinical trial optional)	42
Clinical studies of mental illness not involving clinical trials (collaborative R01)	42
StrokeNet clinical trials and biomarker studies for stroke treatment, recovery and prevention (U01 clinical trial optional).....	43
Collaborative research projects to enhance applicability of mammalian models for translational research (collaborative R01).....	43
Research projects to enhance applicability of mammalian models for translational research (R01)	43



Understanding factors in infancy and early childhood that influence obesity development (R01 clinical trial optional)	43
Self-management for health in chronic conditions (R01 clinical trial optional).....	44
Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R01 clinical trial optional).....	44
Promoting research in basic neuroscience (R01 clinical trial not allowed)	44
Underactive bladder and detrusor activity in ageing (R01 clinical trial optional)	44
Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 clinical trial optional).....	45
Early-life factors and cancer development later in life (R01 clinical trial not allowed) ...	45
Immune system plasticity in the pathogenesis and treatment of complex dental, oral, and craniofacial diseases (R01).....	45
Developing the therapeutic potential of the endocannabinoid system for pain treatment (R01 clinical trial optional)	45
Studies at periviable gestation (R01 clinical trial optional)	46
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional)	46
Research on the mechanisms or behavioural outcomes of multisensory processing (R01 clinical trial optional).....	46
Late stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial required).....	46
Early-stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial optional).....	47
Emerging directions for addressing health disparities in Alzheimer's disease (R03).....	47
Health disparities and Alzheimer's disease (R01).....	47
Major opportunities for research in epidemiology of Alzheimer's disease and cognitive resilience (R01)	47
Understanding Alzheimer's disease in the context of the ageing brain (R01).....	48
Capturing complexity in the molecular and cellular mechanisms involved in the aetiology of Alzheimer's disease (R01)	48
Novel approaches to diagnosing Alzheimer's disease and predicting progression (R01)	48
Personalised strategies to manage symptoms of chronic illness (R01 clinical trial optional).....	48
Innovative questions in symptom science and genomics (R01 clinical trial optional)	49
Applying metabolomics to drive biomarker discovery in symptom science (R01 clinical trial optional)	49
Advancing understanding, prevention, and management of infections transmitted from women to their infants (R01 clinical trial optional)	49
Improving outcomes in cancer treatment-related cardiotoxicity (R01 clinical trial optional).....	49
Clinical development of minimally-invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R01 clinical trial optional).....	50
Education and health: new frontiers (R01 clinical trial optional)	50



Oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R01)	50
Accelerating research on intervertebral disc (R01).....	50
Role of astrocytes and astrocytic networks in drug abuse (R01).....	51
Population health interventions: integrating individual and group level evidence (R01 clinical trials not allowed).....	51
Diet and physical activity assessment methodology (R01)	51
Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R01 clinical trial optional).....	51
Role of mobile genetic elements in cancer (R01).....	52
Metabolic reprogramming to improve immunotherapy (R01).....	52
Non-healing ulcerative wounds in ageing (R01).....	52
Novel approaches to understanding, preventing and treating Lyme disease and tick-borne coinfections (R01).....	52
Gene fusion in paediatric sarcomas (R01)	53
Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial optional).....	53
Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R01).....	53
Characterisation of the adolescent reproductive transition (R01 clinical trial optional).....	53
Safety and outcome measures of pain medications used in children and pregnant women (R01 clinical trial optional)	54
Metabolic contributions to the neurocognitive complications of diabetes: ancillary studies (R01 clinical trial optional).....	54
Phenotypic and functional characterisation of Apolipoprotein E two to inform translation strategies for aging-related conditions (R01).....	54
Assay development and screening to discover therapeutic or imaging agents for diseases of interest to the NIDDK (R01).....	54
Engineering next-generation human nervous system microphysiological systems (R01)	55
Secondary analyses of alcohol and chronic disease (R01).....	55
Symptom management in HIV-infected individuals with comorbid conditions (R01 clinical trial optional).....	55
Trophoblast differentiation and function (R01).....	55
Palliative care needs of individuals with rare advanced diseases and their family caregivers (R01 clinical trial optional)	56
Improving individual and family outcomes through continuity and coordination of care in hospice (R01 clinical trial optional).....	56
Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R01 clinical trial optional)	56
Self-management interventions and technologies to sustain health and optimise functional capabilities (R01 clinical trial optional).....	56



Use of technology to enhance patient outcomes and prevent illness (R01 clinical trial optional).....	57
Improving quality of care and quality of life for persons with Alzheimer’s disease and related dementias at the end of life (R01: clinical trial optional).....	57
Dynamic interactions between systemic or non-neuronal systems and the brain in ageing and in Alzheimer’s disease (R01).....	57
Integrative research to understand the impact of sex differences on the molecular determinants of Alzheimer’s disease risk and responsiveness to treatment (R01).....	57
Translational bioinformatics approaches to advance drug repositioning and combination therapy development for Alzheimer’s disease (R01).....	58
Role of age-associated metabolic changes in Alzheimer’s disease (R01).....	58
Clarifying the relationship between delirium and Alzheimer’s disease and related dementias (R01 clinical trial optional).....	58
Selective cell and network vulnerability in ageing and Alzheimer’s disease (R01 clinical trial not allowed).....	58
Leveraging existing cohort studies to clarify risk and protective factors for Alzheimer’s disease and related dementias (R01).....	59
Promoting caregiver health using self-management (R01 clinical trial optional).....	59
Oral anticancer agents – utilisation, adherence and health care delivery (R01 clinical trial optional).....	59
Potential effects of metformin on ageing and age-related conditions: small-scale clinical studies and secondary analysis of controlled clinical studies (R01 clinical trial optional).....	59
Fertility status as a marker for overall health (R01).....	60
DEADLINE BROUGHT FORWARD: Academic-industrial partnerships to translate and validate in vivo cancer imaging systems (R01 clinical trial optional).....	60
Chronic condition self-management in children and adolescents (R01 clinical trial optional).....	60
Reducing health disparities among minority and underserved children (R01 clinical trial optional).....	60
Reducing overscreening for breast, cervical and colorectal cancers among older adults (R01 clinical trial optional).....	61
Basic mechanisms of brain development mediating substance use and dependence (R01).....	61
Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R01 clinical trial optional).....	61
Advancing our understanding of the brain epitranscriptomics (R01).....	61
Cancer tissue engineering collaborative: enabling biomimetic tissue-engineered technologies for cancer research (R01).....	62
From genomic association to causation: a convergent neuroscience approach for integrating levels of analysis to delineate brain function in neuropsychiatry (U01).....	62
Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R01 clinical trial optional).....	62
Marijuana, prescription opioid or prescription benzodiazepine drug use among older adults (R01 clinical trial optional).....	62



Secondary analysis and integration of existing data to elucidate the genetic architecture of cancer risk and related outcomes (R01).....	63
From genomic association to causation – a convergent neuroscience approach for integrating levels of analysis to delineate brain function in neuropsychiatry (R01).....	63
Effectiveness trials for post-acute interventions and services to optimise longer-term outcomes (R01 clinical trial required).....	63
Therapeutic strategies for the converging TB/T2DM/HIV epidemics (R01).....	63
Discovery of small molecule immunomodulators for cancer therapy (R01)	64
Using small molecules and molecular genetics to identify novel targets and mechanisms contributing to tumour immune evasion (R01)	64
Synthetic biology for engineering (R01 clinical trial optional)	64
Assay development and screening for discovery of chemical probes or therapeutic agents (R01)	64
Interplay of cell death pathways in cancer cell survival and resistance to therapy (R01)	65
Biology of lung, and head and neck preneoplasias (R01).....	65
Secondary analyses of existing alcohol research data (R01)	65
Understanding and modifying temporal dynamics of coordinated neural activity (R01 clinical trial optional).....	65
Research on the health of transgender and gender nonconforming populations (R01 clinical trial optional).....	66
Comparative genomics research programme (R01-clinical trial not allowed)	66
New onset depressive symptoms in acute illness (R01 clinical trial not allowed).....	66
Addressing chronic wound trajectories through social genomics research (R01 – clinical trial optional)	66
Implementing the most successful interventions to improve HIV/AIDS outcomes in US communities (R01 clinical trial optional).....	67
SIREN neurologic clinical trials (U01 clinical trial required).....	67
Fundamental science research on mind and body approaches (R01 clinical trial optional).....	67
Investigator-initiated clinical trials targeting diseases within the mission of NIDDK (R01 clinical trial required).....	67
The application of big data analytics to drug abuse research (R01 clinical trial optional)	68
Revision applications for validation of mobile or wireless health tools for measurement and intervention (R01 clinical trials not allowed).....	68
Revision applications for validation of mobile or wireless health tools for measurement and intervention (R01 clinical trial optional).....	68
Human subjects mechanistic and minimal risk studies (R01 clinical trial optional).....	68
NIDCD clinical trials in communication disorders (R01 clinical trial required)	69
Population health interventions – integrating individual and group level evidence (R01 clinical trial optional).....	69
NIBIB research project grant (R01 clinical trial required)	69



NICHD research project grant (R01 clinical trial required).....	69
Research project grant (parent R01 clinical trial not allowed).....	70
Using information technology to support systematic screening and treatment of depression in oncology practices (R01 clinical trial optional).....	70
End-of-life and palliative care health literacy – improving outcomes in serious, advanced illness (R01 clinical trial optional).....	70
Alzheimer's clinical trials consortium clinical trials (R01 clinical trial required).....	70
Cancer prevention and control clinical trials grant programme (R01 clinical trial required).....	71
Investigator-initiated early phase clinical trials for cancer treatment and diagnosis (R01 clinical trial required).....	71
Traceback testing – increasing identification and genetic counselling of mutation carriers through family-based outreach (U01 clinical trial optional).....	71
Understanding processes of recovery in the treatment of alcohol use disorder (R01 clinical trial optional).....	71
Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01 clinical trial optional).....	72
Disease mechanisms of prenatal and paediatric hydrocephalus (R01 clinical trial not allowed).....	72
Genetics of alcohol sensitivity and tolerance (R01 clinical trial not allowed).....	72
Developmental pharmacodynamics and models of drug effects in paediatrics (R01 clinical trial optional).....	72
Innovative therapies and tools for screenable disorders in newborns (R01 clinical trial optional).....	73
High priority HIV/AIDS research within the mission of the NIDDK (R01 clinical trial optional).....	73
Basic and translational oral health research related to HIV/AIDS (R01 clinical trial not allowed).....	73
Improving patient adherence to treatment and prevention regimens to promote health (R01 clinical trial optional).....	73
Generating new insights and mechanistic understanding of antibiotic resistance development (R01 clinical trial not allowed).....	74
Accelerating basic and translational research in hidradenitis suppurativa (R01 clinical trial not allowed).....	74
Age-related microbiota changes and their implications in chronic disease prevention, treatment and progression (R01 clinical trial optional).....	74
Innovative mental health services research not involving clinical trials (R01).....	74
Identification and management of behavioural symptoms and mental health conditions in individuals with intellectual disabilities (R01 clinical trial optional).....	75
Precision imaging of oral lesions (R01 clinical trial not allowed).....	75
Analyses of CALERIE data and biospecimens to elucidate mechanisms of caloric restriction-induced effects in humans (R01 clinical trial not allowed).....	75



Analyses of adherence strategies and datasets from CALERIE to explore behavioural and psychosocial aspects of sustained caloric restriction in humans (R01 clinical trial not allowed).....	75
Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R01 clinical trial optional)	76
Advancing research needed to develop a universal influenza vaccine (R01 clinical trial not allowed).....	76
Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R01 clinical trial optional).....	76
Novel approaches for relating genetic variation to function and disease (R01 clinical trial not allowed).....	76
Advancing translational and clinical probiotic/prebiotic and human microbiome research (R01 clinical trial optional)	77
Sleep disorders and circadian clock disruption in Alzheimer’s disease and other dementias of ageing (R01 clinical trial not allowed)	77
Building evidence: effective palliative/end of life care interventions (R01 clinical trial optional).....	77
Human cell biology of genetic variants in Alzheimer’s disease (R01 clinical trial not allowed).....	77
BRAIN initiative – development of novel tools to probe cell-specific and circuit-specific processes in human and non-human primate brain (UG3/UH3 clinical trial optional) ...	78
Leveraging cognitive neuroscience to improve assessment of cancer treatment-related cognitive impairment (R21 clinical trial optional)	78
Leveraging cognitive neuroscience to improve assessment of cancer treatment-related cognitive impairment (R01 clinical trial optional).....	78
Predicting behavioural responses to population-level cancer control strategies (R21 clinical trial optional).....	78
Fundamental mechanisms of affective and decisional processes in cancer control (R01 clinical trial optional).....	79
Early phase clinical trials in imaging and image-guided interventions (R01 clinical trial required)	79
Improving smoking cessation in socioeconomically disadvantaged populations via scalable interventions (R01 clinical trial optional)	79
Improving smoking cessation in socioeconomically disadvantaged populations via scalable interventions (R21 clinical trial optional)	79
Single-site investigator-initiated clinical trials (R61/R33: clinical trial required).....	80
Clinical coordinating centre for multi-site investigator-initiated clinical trials (collaborative UG3/UH3 clinical trial required).....	80
Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required)	80
Development of psychosocial therapeutic and preventive interventions for mental disorders (R61/R33 clinical trial required).....	80
Development of psychosocial therapeutic and preventive interventions for mental disorders (R33 clinical trial required).....	81



Clinical trials to test the effectiveness of treatment, preventive, and services interventions (R01 clinical trial required).....	81
Clinical trials to test the effectiveness of treatment, preventive, and services interventions (collaborative R01 clinical trial required).....	81
Pilot effectiveness trials for treatment, preventive and services interventions (R34 clinical trial required).....	81
Administrative supplements for research on dietary supplements (admin supp clinical trial not allowed)	82
Confirmatory efficacy clinical trials of non-pharmacological interventions for mental disorders (R01 clinical trial required).....	82
Prevention research in mid-life adults (R01 clinical trial optional).....	82
Programme to assess the rigour and reproducibility of exosome-derived analytes for cancer detection (R21).....	82
Programme to assess the rigour and reproducibility of exosome-derived analytes for cancer detection (R01).....	83
Early stage testing of pharmacologic or device-based interventions for the treatment of mental disorders (R33 clinical trial required)	83
Early stage testing of pharmacologic or device-based interventions for the treatment of mental disorders (R61/R33 clinical trial required).....	83
Immune response to arthropod blood feeding (R21 clinical trial not allowed).....	83
Ensuring high quality in mentor mother strategy implementation – helping mothers eliminate paediatric HIV in Mozambique.....	84
NEI research grant for vision related secondary data analysis (R21).....	84
Imaging – science track award for research transition (R03 clinical trial optional).....	84
Exploratory or developmental research grant programme (parent R21 clinical trial not allowed).....	84
Pilot and feasibility clinical research grants in urologic disorders (R21 clinical trial optional).....	85
Secondary analyses in obesity, diabetes, digestive and kidney diseases (R21 clinical trial not allowed).....	85
Health promotion among racial and ethnic minority males (R21 clinical trial optional).....	85
Small research grants for oral health data analysis and statistical methodology development (R03).....	85
Small research grant programme (parent R03 clinical trial not allowed).....	86
Mechanisms of alcohol-associated cancers (R21)	86
Prescription drug abuse (R21 clinical trial optional).....	86
Research on autism spectrum disorders (R03 clinical trial optional).....	86
Research on autism spectrum disorders (R21 clinical trial optional).....	86
Pilot and feasibility clinical trials in diabetes, and endocrine and metabolic diseases (R21 clinical trial required).....	87
Exploratory/developmental bioengineering research grants (R21 clinical trial optional)	87
Behavioural and integrative treatment development programme (R03 clinical trial optional).....	87



Mechanisms, models, measurement and management in pain research (R21 clinical trial optional)	87
Drug discovery for nervous system disorders (R21)	88
Chronic condition self-management in children and adolescents (R21 clinical trial optional)	88
Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R21)	88
Alcohol use disorders: treatment, services and recovery research (R03 clinical trial optional)	88
Women and sex or gender differences in drug and alcohol abuse or dependence (R03 clinical trial optional)	89
Women and sex/gender differences in drug and alcohol abuse/dependence (R21 clinical trial optional)	89
Development of animal models and related biological materials for research (R21)	89
Reducing health disparities among minority and underserved children (R21 clinical trial optional)	89
Nutrition and alcohol-related health outcomes (R03)	90
Nutrition and alcohol-related health outcomes (R21)	90
Screening and brief alcohol interventions in underage and young adult populations (R21 clinical trial optional)	90
Small grant programme for new investigators (R03)	90
Public policy effects on alcohol-, marijuana-, and other substance-related behaviours and outcomes (R21)	90
Public policy effects on alcohol-, marijuana-, and other substance-related behaviours and outcomes (R03)	91
Epidemiology and prevention in alcohol research (R21 clinical trial optional)	91
Epidemiology and prevention in alcohol research (R03 clinical trial optional)	91
Alcohol use disorders – treatment, services and recovery research (R21 clinical trial optional)	91
Methodology and measurement in the behavioural and social sciences (R21 clinical trial optional)	92
Research to advance vaccine safety (R21 clinical trial not allowed)	92
Pilot and feasibility studies in preparation for drug and alcohol abuse prevention trials (R34 clinical trial optional)	92
Diet and physical activity assessment methodology (R21 clinical trial not allowed)	92
Behavioural and integrative treatment development programme (R34 clinical trial optional)	93
NEI clinical study planning grant programme (R34)	93
Small research grants for data analysis and statistical methodology applied to genome-wide data (R03)	93
Selected topics in transfusion medicine (R21 clinical trial optional)	93
Multidisciplinary research in vulvodynia (R03)	94
Multidisciplinary research in vulvodynia (R21 clinical trial optional)	94



Hearing health care for adults – improving access and affordability (R21 clinical trial optional)	94
Chemical discovery award (R21/R33)	94
Ethical, legal and social implications of genomics research exploratory/developmental research programme (R21).....	95
Cellular and molecular biology of complex brain disorders (R21).....	95
Development of appropriate paediatric formulations and paediatric drug delivery systems (R03)	95
Development of appropriate paediatric formulations and paediatric drug delivery systems (R21)	95
Healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R21 clinical trial optional)	96
Biomarkers: bridging paediatric and adult therapeutics (R21).....	96
mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R21 clinical trial optional)	96
Health of sexual and gender minority populations (R21 clinical trial optional).....	96
Pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse (R34 clinical trial optional)	97
Environmental exposures and health: exploration of non-traditional settings (R21 clinical trial optional).....	97
Multidisciplinary studies of HIV/AIDS and ageing (R21 clinical trial optional)	97
Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21 clinical trial optional).....	97
Clinical development of minimally invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R21 clinical trial optional).....	98
Examination of survivorship care planning efficacy and impact (R21 clinical trial optional)	98
Effects of in utero alcohol exposure on adult health and disease (R21 clinical trial optional)	98
Dissemination and implementation research in health (R03)	98
Improvement of animal models for stem-cell-based regenerative medicine (R21).....	99
Small research grants for secondary analysis of FaceBase data (R03).....	99
Research grants using the resources from the osteoarthritis initiative (R21 clinical trial not allowed)	99
Advancing the science of geriatric palliative care (R21 clinical trial optional)	99
Secondary data analyses to explore the National Institute of Mental Health research domain criteria (R03)	100
Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03 clinical trial optional)	100
Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21 clinical trial optional)	100
Family-centred self-management of chronic conditions (R21 clinical trial optional)....	100
Alcohol-induced effects on tissue injury and repair (R21)	101



Community partnerships to advance research (R21 clinical trial optional)	101
Self-management for health in chronic conditions (R01 clinical trial optional).....	101
Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R21 clinical trial optional).....	101
Underactive bladder and detrusor activity in ageing (R21 clinical trial optional)	102
Underactive bladder and detrusor activity in ageing (R03 clinical trial optional)	102
Prevention research in mid-life adults (R21 clinical trial optional).....	102
Early-life factors and cancer development later in life (R03 clinical trial not allowed)	102
Early-life factors and cancer development later in life (R21 clinical trial not allowed)	103
Pilot and feasibility clinical research grants in kidney diseases (R21 clinical trial optional)	103
Immune system plasticity in the pathogenesis and treatment of complex dental, oral, and craniofacial diseases (R21).....	103
Pilot services research grants not involving interventions (R34 clinical trial optional)	103
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional)	104
Personalised strategies to manage symptoms of chronic illness (R21 clinical trial optional)	104
Innovative questions in symptom science and genomics (R21 clinical trial optional)..	104
Applying metabolomics to drive biomarker discovery in symptom science (R21 clinical trial optional)	104
Advancing understanding, prevention, and management of infections transmitted from women to their infants (R21 clinical trial optional)	105
Improving outcomes in cancer treatment-related cardiotoxicity (R21 clinical trial optional)	105
Education and health: new frontiers (R21 clinical trial optional)	105
Education and health: new frontiers (R03 clinical trial optional)	105
Oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R21 clinical trial optional)	106
Accelerating research on intervertebral disc (R21).....	106
Zika virus complications (R21 clinical trial optional)	106
Role of astrocytes and astrocytic networks in drug abuse (R21).....	106
Population health interventions: integrating individual and group level evidence (R21 clinical trial not allowed).....	107
Tailoring dental treatment for individuals with systemic diseases that compromise oral health (R21)	107
EXTENDED DEADLINE: Pilot and feasibility studies evaluating the role of ribonucleic acid modifications in cancer biology (R21)	107
Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R21 clinical trial optional).....	108
Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R03 clinical trial optional).....	108



Role of mobile genetic elements in cancer (R21).....	108
Metabolic reprogramming to improve immunotherapy (R21).....	108
Non-healing ulcerative wounds in ageing (R21).....	109
Mechanisms mediating osteoarthritis in ageing (R21).....	109
Novel approaches to understanding, preventing and treating Lyme disease and tick-borne coinfections (R21).....	109
Gene fusion in paediatric sarcomas (R21).....	109
Mechanisms of cancer and treatment-related symptoms and toxicities (R21).....	110
Stimulating innovations in behavioural intervention research for cancer prevention and control (R21 clinical trial optional).....	110
Integrative research on polysubstance abuse and addiction (R21/R33 clinical trial optional).....	110
Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R21).....	110
Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R21): Aids-related.....	111
Characterisation of the adolescent reproductive transition (R03 clinical trial optional).....	111
Characterisation of the adolescent reproductive transition (R21 clinical trial optional).....	111
Safety and outcome measures of pain medications used in children and pregnant women (R03 clinical trial optional).....	111
Safety and outcome measures of pain medications used in children and pregnant women (R21 clinical trial optional).....	112
Small research grants for analyses of data for the Gabriella Miller Kids First Data Resource (R03 clinical trial not allowed).....	112
Target assessment, engagement and data replicability to improve substance use disorders treatment outcomes (R33 clinical trial optional).....	112
Target assessment, engagement and data replicability to improve substance use disorders treatment outcomes (R21/R33 clinical trial optional).....	113
Phenotypic and functional characterisation of Apolipoprotein E two to inform translation strategies for ageing-related conditions (R21).....	113
Secondary analyses of alcohol and chronic disease (R03).....	113
Symptom management in HIV-infected individuals with comorbid conditions (R21 clinical trial optional).....	113
Trophoblast differentiation and function (R21 clinical trial optional).....	114
Palliative care needs of individuals with rare advanced diseases and their family caregivers (R21 clinical trial optional).....	114
Improving individual and family outcomes through continuity and coordination of care in hospice (R21 clinical trial optional).....	114
Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R21 clinical trial optional).....	114
Self-management interventions and technologies to sustain health and optimise functional capabilities (R21 clinical trial optional).....	115



Use of technology to enhance patient outcomes and prevent illness (R21 clinical trial optional).....	115
Improving quality of care and quality of life for persons with Alzheimer’s disease and related dementias at the end of life (R03).....	115
Oral anticancer agents – utilisation, adherence and health care delivery (R21 clinical trial optional)	115
Exploratory analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R21).....	116
Fertility status as a marker for overall health (R21 clinical trial optional).....	116
Reducing overscreening for breast, cervical and colorectal cancers among older adults (R21 clinical trial optional)	116
Juvenile protective factors and their effects on ageing (R03).....	116
Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R21 clinical trial optional).....	117
Advancing our understanding of the brain epitranscriptome (R21).....	117
Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R21 clinical trial optional).....	117
Marijuana, prescription opioid or prescription benzodiazepine drug use among older adults (R21 clinical trial optional).....	117
Marijuana, prescription opioid, or prescription benzodiazepine drug use among older adults (R03)	118
Secondary analysis and integration of existing data to elucidate the genetic architecture of cancer risk and related outcomes (R21).....	118
NICHD exploratory and developmental research grant (R21 clinical trial optional)	118
Pilot effectiveness trials for post-acute interventions and services to optimise longer-term outcomes (R34 clinical trial required)	118
Therapeutic strategies for the converging TB/T2DM/HIV epidemics (R21).....	119
Small grants for secondary analyses of existing data sets and stored biospecimens (R03)	119
Discovery of cell-based chemical probes for novel brain targets (R21).....	119
Interplay of cell death pathways in cancer cell survival and resistance to therapy (R21)	119
NIBIB exploratory/developmental research grant programme (R21 clinical trial optional).....	120
Biology of lung, and head and neck preneoplasias (R21).....	120
Secondary analyses of existing alcohol research data (R03)	120
Understanding and modifying temporal dynamics of coordinated neural activity (R21 clinical trial optional).....	120
Research on the health of transgender and gender nonconforming populations (R21 clinical trial optional).....	121
New onset depressive symptoms in acute illness (R21 clinical trial not allowed).....	121
Implementing the most successful interventions to improve HIV/AIDS outcomes in US communities (R21 – clinical trial optional).....	121



Addressing chronic wound trajectories through social genomics research (R21 – clinical trial optional)	121
Fundamental science research on mind and body approaches (R21 clinical trial optional)	122
Exploratory or developmental research grant programme (Parent R21 clinical trial required)	122
NIMH exploratory/developmental research grant (R21 clinical trial not allowed).....	122
NINDS exploratory neuroscience research grant (R21 clinical trial optional).....	122
Stimulating innovations in behavioural intervention research for cancer prevention and control (R21 clinical trial optional).....	123
Population health interventions – integrating individual and group level evidence (R21 clinical trial optional).....	123
Feasibility clinical trials of mind and body interventions for NCCIH high priority research topics (R34 clinical trial required)	123
NICHD small grant programme (R03 clinical trial optional).....	123
Using information technology to support systematic screening and treatment of depression in oncology practices (R21 clinical trial optional)	124
Human subjects mechanistic and minimal risk studies (R21 clinical trial optional)	124
End-of-life and palliative care health literacy: improving outcomes in serious, advanced illness (R21 clinical trial optional)	124
Pilot and feasibility studies of HIV and animal models for HIV infection within the mission of the NIDDK (R21 clinical trial optional)	124
Understanding processes of recovery in the treatment of alcohol use disorder (R21 clinical trial optional).....	125
NIDA small research grant programme (R03 clinical trial required).....	125
Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21 clinical trial optional).....	125
Tools to enhance the study of prenatal and paediatric hydrocephalus (R21 clinical trial not allowed).....	125
Mechanisms of alcohol tolerance (R21/R33 clinical trial not allowed)	126
Developmental pharmacodynamics and models of drug effects in paediatrics (R03 clinical trial optional).....	126
Innovative therapies and tools for screenable disorders in newborns (R03 clinical trial optional)	126
Innovative therapies and tools for screenable disorders in newborns (R21 clinical trial optional)	127
Basic and translational oral health research related to HIV/AIDS (R21 clinical trial not allowed).....	127
Improving patient adherence to treatment and prevention regimens to promote health (R21 clinical trial optional)	127
Generating new insights and mechanistic understanding of antibiotic resistance development (R21 clinical trial not allowed)	127
Small research grants for establishing basic science-clinical collaborations to understand structural birth defects (R03 clinical trial not allowed).....	128



Accelerating basic and translational research in hidradenitis suppurativa (R21 clinical trial not allowed)	128
Age-related microbiota changes and their implications in chronic disease prevention, treatment and progression (R21 clinical trial optional)	128
In vivo synaptic function in Alzheimer’s disease and related dementias (R21 clinical trial not allowed)	128
Precision imaging of oral lesions (R21 clinical trial not allowed).....	129
Exploratory analyses of CALERIE data and biospecimens to elucidate mechanisms of caloric restriction-induced effects in humans (R21 clinical trial not allowed)	129
Exploratory analyses of adherence strategies and data sets from CALERIE to investigate behavioural and psychosocial aspects of sustained caloric restriction in humans (R21 clinical trial not allowed).....	129
Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R21 clinical trial optional)	129
Advancing research needed to develop a universal influenza vaccine (R21 clinical trial not allowed)	130
Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R03 clinical trial optional).....	130
Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R21 clinical trial optional).....	130
Novel approaches for relating genetic variation to function and disease (R21 clinical trial not allowed).....	130
Innovation grants to nurture initial translational efforts (IGNITE) – neurotherapeutic agent characterisation and in vivo efficacy studies (R61/R33 clinical trial not allowed)	131
Innovation grants to nurture initial translational efforts (IGNITE) – assay development and therapeutic agent identification (R61/R33 clinical trial not allowed).....	131
Innovation grants to nurture initial translational efforts – development and validation of model systems and pharmacodynamic markers to facilitate the discovery of neurotherapeutics (R61/R33 clinical trials not allowed)	131
DEADLINE BROUGHT FORWARD: NCI clinical and translational exploratory or developmental studies (R21 clinical trial optional).....	131
Joint DMS/NIGMS initiative to support research at the interface of the biological and mathematical sciences.....	132
Innovative technologies to deliver genome editing machinery to disease-relevant cells and tissues (UG3/UH3 clinical trial not allowed)	132
Development of cell and tissue platforms to detect adverse biological consequences of somatic cell genome editing (U01 clinical trial not allowed)	132
Expanding the human genome editing repertoire (U01 clinical trial not allowed).....	132
Innovative technologies to non-invasively monitor genome edited cells in vivo (UH2/UH3 clinical trial not allowed)	133
Joint DMS/NIGMS initiative to support research at the interface of the biological and mathematical sciences.....	133
Investigator-initiated genomic medicine research (R01 clinical trial optional)	133
Investigator-initiated genomic medicine research (R21 clinical trial optional)	133



Investigator-initiated genomic medicine research (R01 clinical trial optional).....	134
Investigator-initiated genomic medicine research (R21 clinical trial optional).....	134
COMING SOON: Capacity building assistance for high-impact HIV prevention programme integration	134
Translational neural devices programme (UG3/UH3 clinical trial required).....	134
Advancing extracellular RNA communication research – improved isolation and analysis of exRNA-carrier subclasses (UG3/UH3 clinical trial not allowed).....	135
Advancing extracellular RNA communication research – towards single extracellular vesicle sorting, isolation and analysis of cargo (UG3/UH3 clinical trial not allowed)....	135
Novel assays to address translational gaps in treatment development (UG3/UH3 clinical trial optional)	135
Electronic nicotine delivery systems – basic mechanisms of health effects (R01 clinical trial not allowed)	135
Electronic nicotine delivery systems – population, clinical and applied prevention research (R01 clinical trial optional)	136
Electronic nicotine delivery systems – basic mechanisms of health effects (R21 clinical trial not allowed)	136
Electronic nicotine delivery systems – population, clinical and applied prevention research (R21 clinical trial optional)	136
NCI small grants programme for cancer research (NCI omnibus R03 clinical trial optional).....	136
Neural regulation of cancer (R21).....	137
Neural regulation of cancer (R01).....	137
BRAIN initiative – new concepts and early-stage research for large-scale recording and modulation in the nervous system (R21 clinical trial not allowed)	137
Secondary analyses of existing datasets in heart, lung and blood diseases and sleep disorders (R21)	137
Research answers to the National Cancer Institute’s provocative questions (R21 clinical trials optional)	138
Research answers to the National Cancer Institute’s provocative questions (R01 clinical trial optional)	138
Revision applications to R01 awards for research on the NCI’s provocative questions (R01 clinical trial optional)	138
Revision applications to U01 awards for research on the NCI’s provocative questions (U01 clinical trial optional)	138
NCCIH mind and body clinical trial cooperative agreement (U01): AIDS-related	139
DEADLINE BROUGHT FORWARD: Tobacco use and HIV in low- and middle-income countries (R21 clinical trial optional).....	139
Tobacco use and HIV in low- and middle-income countries (R01 clinical trial optional)	140
Extracellular vesicles and substance use disorders (R01).....	140
Extracellular vesicles and substance use disorders (R21).....	140
Extracellular vesicles and substance use disorders (R21): AIDS-related	141
Extracellular vesicles and substance use disorders (R01): AIDS-related	141



BRAIN initiative – targeted BRAIN circuits projects (R01 clinical trial not allowed)	141
Development of novel non-steroidal contraceptive methods (R61/R33 clinical trial not allowed)	141
Global brain and nervous system disorders research across the lifespan (R21 clinical trial optional)	142
Global brain and nervous system disorders research across the lifespan (R01 clinical trials optional)	142
DEADLINE BROUGHT FORWARD: Emerging global leader award (K43).....	142
Translational research in paediatric and obstetric pharmacology and therapeutics (R21 clinical trial optional).....	142
Translational research in pediatric and obstetric pharmacology and therapeutics (R03)	143
Translational research in pediatric and obstetric pharmacology and therapeutics (R01 clinical trial optional).....	143
Role of epitranscriptomics in development and disease (R01 clinical trial not allowed)	143
Role of epitranscriptomics in development and disease (R21 clinical trial not allowed)	144
Modular R01s in cancer control and population sciences (R01 clinical trial optional) .	144
Leveraging electronic medical records for psychiatric genetic research (R01 clinical trial not allowed)	144
Leveraging electronic medical records for psychiatric genetic research (R01 (collab) clinical trial not allowed).....	144
EXTENDED DEADLINE: Early-stage preclinical validation of therapeutic leads for diseases of interest to the NIDDK (R01)	145
BRAIN Initiative: tools to facilitate high-throughput microconnectivity analysis (R01)	145
Exploring epigenomic or non-coding RNA regulation in the development, maintenance, or treatment of chronic pain (R61/R33 clinical trial optional).....	145
Chronic, non-communicable diseases and disorders across the lifespan – Fogarty international research training award (D43 clinical trial optional).....	146
Integrative omics to enhance therapeutics development for healthy ageing (UH2/UH3 clinical trial not allowed).....	146
Improving implementation of seek, test, treat and retain strategies among people who inject drugs in low- to middle-income countries (R01 clinical trial required).....	146
Elucidating the functional roles of non-coding RNAs in viral infectious diseases (R21 clinical trial not allowed).....	147
Dissemination and implementation research in health (R21 clinical trial optional).....	147
Studies at periviable gestation (R03 clinical trial optional)	147
Studies at periviable gestation (R21 clinical trial optional)	147
Clarifying the relationship between delirium and Alzheimer’s disease and related dementias (R21/R33 clinical trial optional)	148
Investigator-initiated research in computational genomics and data science (R01 clinical trial not allowed)	148



Investigator-initiated research in computational genomics and data science (R21 clinical trial not allowed)	148
Small-cell lung cancer consortium: therapeutic development and mechanisms of resistance (U01).....	148
Exploratory/developmental grants programme for basic cancer research in cancer health disparities (R21 clinical trial not allowed)	149
Basic cancer research in cancer health disparities (R01 clinical trial not allowed).....	149
Efficacy and mechanism evaluation programme – researcher-led workstream: 18/125	149
Early-stage development of informatics technologies for cancer research and management (U01).....	149
Innovative research in cancer nanotechnology (R01).....	150
Development of innovative informatics methods and algorithms for cancer research and management (R21).....	150
Computationally-defined behaviours in psychiatry (R21 clinical trial optional).....	150
Efficacy and mechanism evaluation programme – commissioned calls for proposals: 18/126, 18/127, 18/128, 18/131.....	150
Research for patient benefit programme, round 37 – mental health themed call	151
Image-guided drug delivery (R01 clinical trial optional)	151
DEADLINE BROUGHT FORWARD: NCI clinical and translational exploratory or developmental studies (R21 clinical trial optional): AIDS-related.....	151
Emerging questions in cancer systems biology (U01).....	151
Collaborative research in computational neuroscience programme.....	152
BRAIN initiative – new technologies and novel approaches for large-scale recording and modulation in the nervous system (U01 clinical trial not allowed)	152
BRAIN initiative – optimisation of transformative technologies for large scale recording and modulation in the nervous system (U01 clinical trials not allowed)	152
BRAIN initiative – new technologies and novel approaches for large-scale recording and modulation in the nervous system (R01 clinical trial not allowed).....	152
Drug transport across the blood-testis and blood-epididymal barriers (R61/R33 clinical trial not allowed).....	153
Discovery of biomarkers, biomarker signatures and endpoints for pain (R61/R33 clinical trial optional).....	153
Programme grants for applied research, competition 28 – mental health themed call.	153
Programme development grants – competition 23	153
Cancer tissue engineering collaborative: enabling biomimetic tissue-engineered technologies for cancer research (U01)	154
Sustained release innovation for HIV (R61/R33 clinical trial optional)	154
Expanding extramural research opportunities at the NIH clinical centre (U01 clinical trial optional)	154
Telomeres as sentinels of environmental exposures, psychosocial stress, and disease susceptibility – a methods comparison study (U01 clinical trial optional).....	155
Novel approaches to safe, non-invasive, real time assessment of human placenta development and function across pregnancy (R01 clinical trial not allowed).....	155



Novel approaches to safe, non-invasive, real time assessment of human placenta development and function across pregnancy (R21 clinical trial not allowed).....	155
Halting tuberculosis transmission in HIV-endemic and other high-transmission settings (R01 clinical trial not allowed)	156
HIV drug resistance – genotype-phenotype-outcome correlations (R01 clinical trial not allowed).....	156
Systems developmental biology for understanding embryonic development and the ontogeny of structural birth defects (R01)	156
Clinical, behavioural and physiological research testing current and novel closed loop systems (R01 clinical trial required).....	156
Mechanisms underlying the contribution of type 1 diabetes disease-associated variants (R01 clinical trial not allowed)	157
Impact of the use of glucose monitoring and control technologies on health outcomes and quality of life in older adults with type 1 diabetes (R01 clinical trial required)	157
Detection of HIV for self-testing (R61/R33)	157
Immune system engineering for targeted tolerance in type 1 diabetes (R01 clinical trial not allowed)	157
Characterisation and discovery of novel autoantigens and epitopes in type 1 diabetes (R01 clinical trial optional)	158
Understanding skeletal effects of type 1 diabetes (R01 clinical trial optional).....	158
Understanding skeletal effects of type 1 diabetes (R01 clinical trial optional).....	158
Investigator initiated extended clinical trial (R01 clinical trial required).....	158
Investigator initiated extended clinical trial (R01 clinical trial required): AIDS-related	159
Imaging and biomarkers for early detection of aggressive cancer (U01).....	159
BRAIN initiative – proof of concept development of early stage next generation human brain imaging (R01 clinical trials not allowed).....	159
BRAIN initiative – development of next generation human brain imaging tools and technologies (U01 clinical trials not allowed).....	159
Modelling and simulation to optimise HIV prevention research (R01 clinical trial not allowed).....	160
Cutting-edge basic research awards (R21 clinical trial optional)	160



OCTOBER

Serious adverse drug reaction research (R21)

NIH: National Human Genome Research Institute

This R21 funding opportunity announcement supports research projects that will advance the state of knowledge of serious adverse drug reactions, particularly those that are idiosyncratic. Direct costs are limited to \$275,000 over a two-year period, with

no more than \$200,000 in direct costs allowed in any single year. The maximum project period is two years.

Closing date: 01 Oct 18

[Link to *Research Professional](#)

Serious adverse drug reaction research (R01)

NIH: National Human Genome Research Institute

This R01 funding opportunity announcement supports research projects that will advance the state of knowledge of serious adverse drug reactions, particularly those that are idiosyncratic. Application budgets are

not limited, but must reflect the actual needs of the project. The maximum project period is four years.

Closing date: 01 Oct 18

[Link to *Research Professional](#)

Novel genomic technology development (R01 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports high risk and high reward research that catalyses major advances in genomics through technology development in other fields than nucleic acid sequencing. Grants are worth up to

USD 700,000 each per year for a maximum period of four years.

Closing date: 02 Oct 18

[Link to *Research Professional](#)

Novel genomic technology development (R21 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports high risk and high reward research that catalyses major advances in genomics through technology development in other fields than nucleic

acid sequencing. Grants are worth up to USD 400,000 each over three years.

Closing date: 02 Oct 18

[Link to *Research Professional](#)



Human Heredity and Health in Africa consortium biorepository (U24 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports cooperative agreements to further develop and sustain up to three Human Heredity and Health in Africa biorepositories by building on existing infrastructure. Grants are

worth up to USD 1 million per year for a maximum period of three years.

Closing date: 03 Oct 18

[Link to *Research Professional](#)



NCCIH mind and body clinical trial cooperative agreement (U01)

NIH: National Center for Complementary and Integrative Health

This supports investigator-initiated clinical trials of mind and body interventions to be used in future multi-site trials. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

Closing date: 03 Oct 18

[Link to *Research Professional](#)



BRAIN Initiative – tools to target, identify and characterise non-neuronal cells in the brain (R01– clinical trial not allowed)

NIH: National Institute on Drug Abuse

This aims to stimulate the development and validation of novel tools and analytical methods to target, identify and characterise non-neuronal cells in the brain. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is three years.

Closing date: 04 Oct 18

[Link to *Research Professional](#)



BRAIN initiative – biology and biophysics of neural stimulation (R01 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This supports projects to systematically characterise, model and validate the membrane, cellular, circuit and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 04 Oct 18

[Link to *Research Professional](#)





Immune mechanisms at the maternal-foetal interface (R01 clinical trial optional)

NIH: National Institute of Allergy and Infectious Diseases

This supports research to determine the roles and interactions of immune cells at the maternal-foetal interface throughout pregnancy that protect or impact the foetus and that may influence foetal immune system

development. Funding is for up to five years.

Closing date: 04 Oct 18

[Link to *Research Professional](#)

Dissemination and implementation research in health (R01 clinical trial optional)

NIH: National Institute of Mental Health

This encourages investigators to submit research grant applications that will identify, develop, test, evaluate or refine strategies to disseminate and implement evidence-based practices into public health, clinical practice, and community settings. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

The health of sexual and gender minority populations (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health of sexual and gender minority populations and that leads to the development of health interventions and health service

delivery methods. Application budgets are not limited. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Prescription drug abuse (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to develop innovative research on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse and to develop effective prevention and service delivery approaches and behavioural and pharmacological treatments.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Diet and physical activity assessment methodology (R01 clinical trial not allowed)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports innovative research to enhance the quality of measurements of dietary intake and physical activity. Application budgets are not limited but need to reflect the actual costs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



International research collaboration on drug abuse and addiction research (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Application budgets are not limited but must reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





Bioengineering research grants (R01 clinical trial optional)

NIH: National Institute of Biomedical Imaging and Bioengineering

These aim to foster the development of an innovative technology, model, technique, design or method that has the potential for significant impact on biomedical research by infusing principles and concepts from the quantitative sciences. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum award period is five years depending on the policy of each NIH Institute.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Behavioural and integrative treatment development programme (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to encourage behavioural intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations and ascertain best sequencing of behavioural, combined, sequential or integrated

behavioural and pharmacological drug abuse treatment and interventions. Application budgets are not limited but must reflect the actual needs of the project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Modelling of infectious disease agent study research projects (R01)

NIH: National Institute of General Medical Sciences

This supports innovative research that will develop and apply computational tools and methods for modelling interactions between infectious agents and their hosts, disease spread, prediction systems and response

strategies. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





Women and sex or gender differences in drug and alcohol abuse or dependence (R01 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This aims to advance identification of male-female differences in drug and alcohol research outcomes and to advance research specific to women or

highly relevant to women. Funding is for five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Advancing erythroid cell biology (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This R01 funding opportunity announcement supports research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components contribute to erythropoiesis. Application budgets are

not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Ethical, legal and social implications of genomic research regular research programme (R01)

NIH: National Human Genome Research Institute

This supports studies on the ethical, legal and social implications of human genome research. Application budgets are not limited but need to reflect the

actual needs of the proposed project over up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Ancillary studies to major ongoing clinical research studies to advance areas of scientific interest within the mission of the NIDDK (R01 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This seeks to accelerate the pace and expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the National Institute of Diabetes

and Digestive and Kidney Diseases' mission. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Addressing health disparities in NIDDK diseases (R01 clinical trial not allowed)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This aims to improve understanding of the causes of high priority diseases in the US and mitigate health disparities. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Mechanisms, models, measurement and management in pain research (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This announcement aims to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these institutes and centres. Applications budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Research project grant (parent R01 clinical trial required)

NIH: National Institutes of Health

This supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigators. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R01)

NIH: National Institute on Drug Abuse

This announcement encourages basic functional genomic research that identifies genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use disorders. Applications budgets are

not limited, but must reflect the needs of the project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Nutrition and alcohol-related health outcomes (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on associations between nutrition and alcohol-related health outcomes in humans and animal models. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Screening and brief alcohol interventions in underage and young adult populations (R01 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations. Application budgets are not limited, but must reflect the actual

needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Health promotion among racial and ethnic minority males (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate and expand research in the health of minority men. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Public policy effects on alcohol-, marijuana, and other substance-related behaviours and outcomes (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

The aim is to encourage research on the effects of public policies of health-related behaviours and outcomes associated with alcohol, marijuana, and other substances. Application budgets are not limited but must reflect the

actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Epidemiology and prevention in alcohol research (R01 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms and alcohol use disorders. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Programme for extramural or intramural alcohol research collaborations (U01 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This encourages collaboration between alcohol researchers in the extramural community and those within the National Institute on Alcohol Abuse and Alcoholism intramural research

programme. Grants are worth up to USD 250,000 per year for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Genetic susceptibility and variability of human structural birth defects (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports innovative applications that will inform understanding of structural birth defects through the use of animal models in conjunction with translational or clinical approaches. Grants are worth up to USD 499,999 per

year for projects of up to five years in duration.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

NLM research grants in biomedical informatics and data science (R01 clinical trial optional)

NIH: National Library of Medicine

This supports innovative research and development in biomedical informatics and data science. Grants are worth up to USD 250,000 each per year over a maximum period of four years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Investigations on primary immunodeficiency diseases/inborn errors of immunity (R01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports projects aiming to advance the discovery, characterisation and treatment of primary immunodeficiency diseases. Funding is for five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Methodology and measurement in the behavioural and social sciences (R01 clinical trial optional)

NIH: Office of the Director

This supports applications aimed at improving and developing methodology in the behavioural and social sciences through innovations in research designs, measurement, data collection and data analysis techniques. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Research to advance vaccine safety (R01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports research that will contribute to the overall understanding of vaccine safety. Funding is for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Secondary analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R01)

NIH: National Institute on Aging

This supports applications employing secondary analysis of existing data sets or stored biospecimens, to address clinically related issues on ageing changes influencing health across the lifespan, and on diseases and disabilities in older persons. Applications budgets

are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Drug discovery for nervous system disorders (R01)

NIH: National Institute of Mental Health

This announcement aims to stimulate the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. Application budgets are not limited, but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports the innovative analysis of existing social science, behavioural, administrative and neuroimaging data to study the etiology and epidemiology of drug-using behaviours and related disorders, prevention of drug use and

HIV and health service use. Direct costs are limited to USD 500,000 per year over a maximum period of five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Obesity policy evaluation research (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement encourages evaluations of large scale policies or programmes that are expected to influence obesity-related behaviours or weight outcomes in an effort to prevent or reduce obesity. Applications budgets

are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Selected topics in transfusion medicine (R01 clinical trial optional)

NIH: National Heart, Lung and Blood Institute

This encourages applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Stimulating haematology investigation – new endeavours (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports innovative, high-quality haematology research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney

Diseases. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Alzheimer's drug development programme (U01 clinical trial optional)

NIH: National Institute on Aging

This supports preclinical and early stage clinical development of small-molecule and biologic therapeutic agents that prevent Alzheimer's disease, slow its progression or treat its cognitive and behavioural symptoms.

Funding is worth up to USD 1 million per project per year for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Advances in polycystic kidney disease (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement aims to increase investigator interest in basic and applied investigations of the etiology and pathogenesis of polycystic kidney disease, in both its autosomal dominant and autosomal recessive forms. Application budgets are not limited, but

need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Multidisciplinary research in vulvodynia (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





Research on autism spectrum disorders (R01 clinical trial optional)

NIH: National Institute of Mental Health

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders. Application budgets are not limited, but must reflect

the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Mechanisms of alcohol-associated cancers (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research that investigates cellular and molecular mechanisms by which alcohol increases cancer risk. Application budgets are not limited, but must reflect the actual needs of the

project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Natural history of disorders identifiable by screening of newborns (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



NINDS exploratory clinical trials (U01 clinical trial required)

NIH: National Institute of Neurological Disorders and Stroke

This supports investigator-initiated exploratory clinical trials within the mission and research interests of the National Institute of Neurological Disorders and Stroke. Application budgets are not limited but must reflect

the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





NINDS efficacy clinical trials (U01 clinical trial required)

NIH: National Institute of Neurological Disorders and Stroke

This supports investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke. Application budgets are not limited, but need to reflect the actual

needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Novel biomarkers for the development of HIV incidence assays with improved specificity (R01 clinical trial optional)

NIH: National Institute of Allergy and Infectious Diseases

This supports the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguished recent from chronic infections. Application budgets are not limited but

need to reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Hearing health care for adults – improving access and affordability (R01 clinical trial optional)

NIH: National Institute on Deafness and other Communication Disorders

This supports research on hearing healthcare in adults in support of improving access and affordability. Application budgets are not limited, but must reflect the actual needs of the

project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Preclinical research on model organisms to predict treatment outcomes for disorders associated with intellectual and developmental disabilities (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages preclinical research in model organisms of neurodevelopmental disorders. Application budgets are limited to

US\$499,999 per year over a period of up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Outcome measures for use in treatment trials for individuals with intellectual and developmental disabilities (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This encourages applications from institutions that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities. Application budgets are

limited to USD 499,999 per year over a five-year period.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Ancillary studies to the NIDDK intestinal stem cell consortium (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement seeks applications to conduct ancillary studies to the NIDDK intestinal stem cell consortium. Application budgets are not limited but should reflect actual needs of the

proposed projects. The maximum period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Obesity and asthma – awareness and self-management (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to encourage research that examines the relationship between asthma, obesity and self-management. Application budgets are not limited but should reflect the actual needs of the

project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Cellular and molecular biology of complex brain disorders (R01)

NIH: National Institute of Mental Health

This encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. Application budgets are not

limited but must reflect the actual needs of the proposed project. The total project period may not exceed five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Development of appropriate paediatric formulations and paediatric drug delivery systems (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Application budgets are not limited, but should

reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Advancing basic neurobiology toward translation through assay development (R01 clinical trial not allowed)

NIH: National Institute of Mental Health

This aims to develop novel, robust assays to reveal changes in neuronal or glial function. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is four years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Healthy habits – timing for developing sustainable healthy behaviours in children and adolescents (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 18. Application budgets are not limited, but need to reflect actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate research utilising mobile health tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. Application budgets are not limited, but need to reflect

actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



NeuroNEXT clinical trials (U01 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This invites applications for exploratory clinical trials of investigational agents that may contribute to the justification for designing a future trial, for biomarker validation studies or for proof of mechanism clinical studies.

Application budgets are not limited, but need to reflect actual needs of the project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Mechanisms mediating osteoarthritis in ageing (R01)

NIH: National Institute on Aging

This announcement encourages and accelerates the characterisation of new or underutilised models and the testing of hypotheses that will lead to an improved understanding of the mechanisms mediating osteoarthritic progression. Application budgets are

not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Discovery of in vivo chemical probes for novel brain targets (R01)

NIH: National Institute of Mental Health

This supports investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. Application budgets are not limited but need to

reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Maternal nutrition and pre-pregnancy obesity – effects on mothers, infants and children (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Environmental exposures and health: exploration of non-traditional settings (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities across the lifespan for those living or spending time in non-traditional settings such as playgrounds and

nursing homes. Application budgets are not limited, but must reflect the actual needs of the project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional)

NIH: National Institute on Aging

This supports studies addressing HIV and ageing that aim to improve understanding of biological, clinical and socio-behavioural aspects of ageing through the lens of HIV infection and its treatment. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Juvenile protective factors and their effects on ageing (R01)

NIH: National Institute on Aging

This call supports descriptive studies identifying putative juvenile protective factors, experimental studies testing hypotheses about their effects on ageing and translational studies exploring the potential risks and benefits of maintaining or modulating the level of juvenile protective factors in adult life.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R01 clinical trial optional)

NIH: National Cancer Institute

This encourages transdisciplinary and translational research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect

cancer prognosis and survival. Funding is for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Examination of survivorship care planning efficacy and impact (R01 clinical trial optional)

NIH: National Cancer Institute

This aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up

care for cancer survivors. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Effects of in utero alcohol exposure on adult health and disease (R01 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Application budgets are not limited, but must reflect the actual needs of the

project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Improvement of animal models for stem-cell-based regenerative medicine (R01)

NIH: Office of the Director

This R01 funding opportunity announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. Application budgets are not limited, but must reflect

the actual needs of the proposed project. The maximum project period is five year.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Research on comparative effectiveness and implementation of HIV/AIDS and alcohol interventions (R01 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Application budgets must not exceed

USD 500,000 per year in direct cost. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Biomarkers for diabetes, digestive, kidney and urologic diseases using biosamples from the NIDDK repository (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports assays and data analysis of repository-held samples for studies focused on a disease relevant to the institute. Application budgets are

limited to USD 250,000 in direct costs per year for a maximum of three years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Research grants using the resources from the osteoarthritis initiative (R01 clinical trial not allowed)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

These support research focused on the use of the osteoarthritis initiative database, clinical data and images. Applications budgets are not limited, but must reflect the needs of the project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Advancing the science of geriatric palliative care (R01 clinical trial optional)

NIH: National Institute on Aging

This supports research focused on palliative care in geriatric populations. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports research to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies. Application budgets are not limited, but

need to reflect actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Family-centred self-management of chronic conditions (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages research that seeks to build the science of family-centred self-management in chronic conditions. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Alcohol-induced effects on tissue injury and repair (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Application budgets are not limited but need to reflect the actual

needs of the project over a period of up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Community partnerships to advance research (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages researchers to partner with community groups, using community engaged research methodologies that will enhance relationships and lead to better intervention development and positive health outcomes. Application budgets

are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Clinical studies of mental illness not involving clinical trials (collaborative R01)

NIH: National Institute of Mental Health

This supports collaborative clinical studies that do not involve treatment development, efficacy, or effectiveness trials. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





StrokeNet clinical trials and biomarker studies for stroke treatment, recovery and prevention (U01 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This encourages multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trails in stroke prevention, treatment and recovery.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Collaborative research projects to enhance applicability of mammalian models for translational research (collaborative R01)

NIH: National Cancer Institute

This supports collaborative projects from multidisciplinary teams to expand, improve, or transform the utility of mammalian cancer and tumour models for translational research. Application budgets are limited to USD 450,000

direct costs per year. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Research projects to enhance applicability of mammalian models for translational research (R01)

NIH: National Cancer Institute

This supports research demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for

patients' benefit. Application budgets are limited to USD 450,000 in direct costs per year for a maximum of five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Understanding factors in infancy and early childhood that influence obesity development (R01 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This seeks applications that propose to characterise or identify factors in early childhood that may increase or mitigate risk for obesity or excessive weight gain or to fill methodological research gaps relevant to the understanding of risk for development of obesity in children.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





Self-management for health in chronic conditions (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This supports research that seeks to build the science of self-management for health in chronic conditions. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Promoting research in basic neuroscience (R01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This aims to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Underactive bladder and detrusor activity in ageing (R01 clinical trial optional)

NIH: National Institute on Aging

This supports basic, clinical or translational research on underactive bladder and detrusor underactivity, and the consequences in ageing and in older persons. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 clinical trial optional)

NIH: National Cancer Institute

This supports efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent and manage disease. Application

budgets are not limited but must reflect the needs of the project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Early-life factors and cancer development later in life (R01 clinical trial not allowed)

NIH: National Cancer Institute

This aims to stimulates research focused on the role of early-life factors in cancer development in later life. Application budgets are not limited but need to reflect the actual needs of the

proposed projects. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Immune system plasticity in the pathogenesis and treatment of complex dental, oral, and craniofacial diseases (R01)

NIH: National Institute of Dental and Craniofacial Research

This announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on

precise modulation of the immune system. Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Developing the therapeutic potential of the endocannabinoid system for pain treatment (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports projects that seek to elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Studies at periviable gestation (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Research on the mechanisms or behavioural outcomes of multisensory processing (R01 clinical trial optional)

NIH: National Institute on Aging

This supports research to elucidate the mechanisms or behavioural outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and

cognate perceptual quality. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Late stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial required)

NIH: National Institute on Aging

This supports the development and implementation of late stage clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's

disease spectrum from pre-symptomatic to more severe stages of disease. Funding is for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Early-stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial optional)

NIH: National Institute on Aging

This supports the development and implementation of early-stage clinical trials of promising pharmacological and non-pharmacological interventions related to age-related cognitive decline and Alzheimer's disease. Funding is for

up to five years. The total budget for the fiscal year 2019 is USD 10 million, funding 10 to 15 grants.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Emerging directions for addressing health disparities in Alzheimer's disease (R03)

NIH: National Institute on Aging

These support health disparities research related to Alzheimer's disease, including the study of biological, behavioural, sociocultural and environmental factors that influence population level health differences. The initiative intends to commit a total estimated budget of US\$2 million in

fiscal year 2016 to fund 15 to 20 awards. Budgets are limited to US\$50,000 in direct costs per year. The maximum project period is two years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Health disparities and Alzheimer's disease (R01)

NIH: National Institute on Aging

These support health-disparities research related to Alzheimer's disease, including the study of biological, behavioural, sociocultural, and environmental factors that influence population level health differences. The initiative intends to commit a total estimated budget of US\$10 million in

fiscal year 2016 to fund 10 to 12 awards. Budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Major opportunities for research in epidemiology of Alzheimer's disease and cognitive resilience (R01)

NIH: National Institute on Aging

This encourages investigator-initiated applications addressing the epidemiology of Alzheimer's disease, as well as protective factors for cognitive health and resilience. NIH intends to commit a total of US\$12 million to fund an estimate of 10 to 15 awards for fiscal

year 2016. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Understanding Alzheimer's disease in the context of the ageing brain (R01)

NIH: National Institute on Aging

This announcement encourages research that aims to establish the role and impact of brain ageing in the development and progression of Alzheimer's disease. NIA intends to commit a total of US\$10 million to fund

approximately 20 to 25 awards for fiscal year 2016.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Capturing complexity in the molecular and cellular mechanisms involved in the aetiology of Alzheimer's disease (R01)

NIH: National Institute on Aging

This announcement aims to support innovative research focused on understanding the molecular and cellular mechanisms underlying the heterogeneity and multi-factorial nature of Alzheimer's disease with the potential to create new or challenge existing scientific paradigms.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Novel approaches to diagnosing Alzheimer's disease and predicting progression (R01)

NIH: National Institute on Aging

This announcement aims to identify novel biomarkers to diagnose Alzheimer's disease and to predict clinical course. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Personalised strategies to manage symptoms of chronic illness (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Innovative questions in symptom science and genomics (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified innovative questions in symptom and genomic nursing science. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Applying metabolomics to drive biomarker discovery in symptom science (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages applications on biomarker discovery that utilise metabolomics approaches to advance the understanding, assessment and management of symptoms. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Advancing understanding, prevention, and management of infections transmitted from women to their infants (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This stimulates investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and

delivery and breastfeeding. The maximum period of projects is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Improving outcomes in cancer treatment-related cardiotoxicity (R01 clinical trial optional)

NIH: National Cancer Institute

This supports collaborative projects that contribute to the identification and characterisation of patients at risk of developing cancer treatment-related cardiotoxicity. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Clinical development of minimally-invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This encourages research project grant (R01) applications from institutions or organisations that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. Total direct costs budget

should be less than USD 500,000 per year. The maximum project period is three years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Education and health: new frontiers (R01 clinical trial optional)

NIH: National Cancer Institute

This supports research that will further elucidate the pathways involved in the relationship between education and health outcomes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement encourages applications from the scientific community to support outstanding research in the area of oocyte mitochondrial function in relation to fertility, ageing and mitochondrial disease transmission to offspring.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Accelerating research on intervertebral disc (R01)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

This announcement encourages studies on basic biology of the intervertebral disc and seeks applications that accelerate an understanding of basic research on the intervertebral disc and develop new directions on the factors that lead to disc degeneration.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Role of astrocytes and astrocytic networks in drug abuse (R01)

NIH: National Institute on Drug Abuse

This announcement aims to examine the effects of drugs of abuse on the structural connectivity of astrocytic networks within the central nervous system, and the generation, processing and spatiotemporal control of activities within these networks. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Population health interventions: integrating individual and group level evidence (R01 clinical trials not allowed)

NIH: Office of the Director

This supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Diet and physical activity assessment methodology (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This announcement aims to enhance the quality of measurements of dietary intake and physical activity. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This aims to establish a programme of research to advance the understanding, prevention and treatment of paediatric multiple organ dysfunction syndrome. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Role of mobile genetic elements in cancer (R01)

NIH: National Institutes of Health

This R01 funding opportunity announcement aims to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements in cancer. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Metabolic reprogramming to improve immunotherapy (R01)

NIH: National Cancer Institute

This announcement aims to generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use

this information to manipulate the metabolic pathways used by the tumour, the immune response, or both to improve cancer immunotherapy.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Non-healing ulcerative wounds in ageing (R01)

NIH: National Institute on Aging

This announcement seeks applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in ageing and in older persons. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Novel approaches to understanding, preventing and treating Lyme disease and tick-borne coinfections (R01)

NIH: National Institute of Allergy and Infectious Diseases

This R01 funding opportunity announcement supports research that will contribute to the overall understanding of Lyme disease and co-infections transmitted by Ixodes ticks. Application budgets are not limited but

must reflect the needs of the project. The maximum funding period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Gene fusion in paediatric sarcomas (R01)

NIH: National Cancer Institute

This R01 funding opportunity announcement encourages applications that explore the molecular biology of paediatric sarcomas to elucidate molecular mechanisms by which fusion genes and the resulting protein products drive tumorigenesis and

cancer progression. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial optional)

NIH: National Institute of Mental Health

This supports research on the development of novel radioligands for positron emission tomography or single photon emission computed tomography imaging in the human brain. Budgets are not limited but need to reflect the

actual needs of the proposed project. The maximum project period is three years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R01)

NIH: National Institute of Dental and Craniofacial Research

This supports research on mechanisms underlying the manifestations of sex-based differences in dental, oral and craniofacial related diseases and conditions. Application budgets are not limited but need to reflect the actual

needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Characterisation of the adolescent reproductive transition (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research in the area of puberty and the trajectory of sexual development. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Safety and outcome measures of pain medications used in children and pregnant women (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations and develop effective instruments or approaches to assess and evaluate maternal and child

outcomes of pain medication treatments. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Metabolic contributions to the neurocognitive complications of diabetes: ancillary studies (R01 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports human studies aiming to elucidate the aetiology and pathogenesis of the increased risk for neurocognitive impairment associated with type two diabetes. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Phenotypic and functional characterisation of Apolipoprotein E two to inform translation strategies for aging-related conditions (R01)

NIH: National Institute on Aging

This supports basic and translational studies on ApoE2 and other variants to improve understanding of physiologic and cellular differences attributable to the ApoE e2 allele, versus other ApoE alleles, and how they mediate ApoE e2's differential effects on longevity and risk for age-related conditions. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Assay development and screening to discover therapeutic or imaging agents for diseases of interest to the NIDDK (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This aims to to develop, validate, or conduct a screen using a novel assay to identify therapeutic or imaging agents relevant to health related outcomes of interest to the NIDDK. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Engineering next-generation human nervous system microphysiological systems (R01)

NIH: National Institute of Mental Health

This announcement aims to stimulate basic research to develop next-generation human cell-derived microphysiological systems with improved fidelity to complex human brain, spinal, peripheral nervous system and sensory end organ circuit physiology in vivo. Applications budgets

are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Secondary analyses of alcohol and chronic disease (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages research that uses existing datasets to examine associations between alcohol and non-communicable chronic diseases in order to facilitate innovative and cost-effective research using previously collected data. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project duration is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Symptom management in HIV-infected individuals with comorbid conditions (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This supports the development, adaptation and testing of innovative cost-effective strategies to prevent, identify and manage symptoms of HIV-associated non-AIDS conditions and other comorbidities among older adults with prolonged HIV infection.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Trophoblast differentiation and function (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This encourages applications from the scientific community to support outstanding research in the area of trophoblast differentiation and function in relation to fertility and pregnancy, including the role of the immune system. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Palliative care needs of individuals with rare advanced diseases and their family caregivers (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks to expand knowledge and increase the evidence base for palliative care in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Improving individual and family outcomes through continuity and coordination of care in hospice (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks to stimulate research that focuses on reducing negative individual and family outcomes related to unwanted transitions at the end of life and optimising the individual and family outcomes related to high quality coordination of care of individuals who are enrolled in hospice. Applications

budgets are not limited but need to reflect the actual need of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate clinical research addressing behavioural and psychological symptoms of dementia and the association of BPSD with unmet physical, social or environmental needs in persons with dementia. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Self-management interventions and technologies to sustain health and optimise functional capabilities (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This supports research on self-management interventions and technologies that improve health and quality of life in persons needing assistance to optimise and maintain existing functional capabilities, prevent or delay disabilities and navigate their

environment. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Closing date: 05 Oct 18

[Link to *Research Professional](#)



Use of technology to enhance patient outcomes and prevent illness (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks clinical research focused on the development and utilisation of technologies that can help address patient outcomes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Improving quality of care and quality of life for persons with Alzheimer's disease and related dementias at the end of life (R01: clinical trial optional)

NIH: National Institute on Aging

This aims to address clinical and translational research gaps in the study of end-of-life care needs in order to improve quality of life at the end of life of people with Alzheimer's disease and related dementias and their families. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Dynamic interactions between systemic or non-neuronal systems and the brain in ageing and in Alzheimer's disease (R01)

NIH: National Institute on Aging

This supports research projects on the role of ageing-related changes in systemic, peripheral, and non-neuronal factors individually or in combination to

the pathogenesis, presentation, and progression of Alzheimer's disease.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Integrative research to understand the impact of sex differences on the molecular determinants of Alzheimer's disease risk and responsiveness to treatment (R01)

NIH: National Institute on Aging

This seeks applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain ageing and phenotypes of Alzheimer's disease risk and on the responsiveness to

pharmacologic and non-pharmacologic interventions. Application budgets are worth up to USD 750,000 per year for a maximum period of five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Translational bioinformatics approaches to advance drug repositioning and combination therapy development for Alzheimer's disease (R01)

NIH: National Institute on Aging

This seeks applications that integrate the use of computational approaches to identify individual drugs currently used for other conditions with potential to be efficacious in AD or AD-related dementias with proof-of-concept efficacy studies in cell-based models,

animal models and humans. Application budgets are worth up to USD 500,000 per year for maximum period of five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Role of age-associated metabolic changes in Alzheimer's disease (R01)

NIH: National Institute on Aging

This seeks innovative experimental approaches to explore the molecular and cellular bases for age-related change in metabolism that impact the development of Alzheimer's disease. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Clarifying the relationship between delirium and Alzheimer's disease and related dementias (R01 clinical trial optional)

NIH: National Institute on Aging

This aims to clarify the relationship between delirium and Alzheimer's disease and related dementias. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Selective cell and network vulnerability in ageing and Alzheimer's disease (R01 clinical trial not allowed)

NIH: National Institute on Aging

This aims to define and characterise neural cell populations, neural circuits and brain networks and regions that are vulnerable to brain ageing and Alzheimer's disease. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Leveraging existing cohort studies to clarify risk and protective factors for Alzheimer's disease and related dementias (R01)

NIH: National Institute on Aging

This supports applications that will combine multiple cohorts in order to improve statistical power and clarify risk and protective factors for Alzheimer's disease and related dementias. The total budget is worth USD 8 million to fund five to eight awards in fiscal year 2017. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Promoting caregiver health using self-management (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate research in promoting informal caregiver health using self-management. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Oral anticancer agents – utilisation, adherence and health care delivery (R01 clinical trial optional)

NIH: National Cancer Institute

This aims to assess and describe the current state of oral anticancer medication utilisation, delivery and adherence, identify structural, systemic, and psychosocial barriers to adherence and develop models and strategies to improve safe and effective delivery of

these agents so that clinical outcomes are optimised. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Potential effects of metformin on ageing and age-related conditions: small-scale clinical studies and secondary analysis of controlled clinical studies (R01 clinical trial optional)

NIH: National Institute on Aging

This supports research projects including small-scale physiologic studies in humans or secondary analyses of data and stored biospecimens from controlled clinical intervention studies, to increase the understanding of the clinical

translational potential of metformin to delay deleterious ageing changes or to extend healthy human life span. Application budgets need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Fertility status as a marker for overall health (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research that explores the premise that fertility status can be a marker for overall health. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



DEADLINE BROUGHT FORWARD: Academic-industrial partnerships to translate and validate in vivo cancer imaging systems (R01 clinical trial optional)

NIH: National Cancer Institute

*** The closing date for this opportunity has been brought forward. The previous deadline of 1 March 2018 has been brought forward to 5 February 2018. All other call details remain unchanged. This programme aims to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems

in cancer biology, risk of cancer development, diagnosis, treatment, and disease status. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Chronic condition self-management in children and adolescents (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages research that aims to improve self-management and quality of life in children and adolescents with chronic conditions. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Reducing health disparities among minority and underserved children (R01 clinical trial optional)

NIH: National Institutes of Health

This encourages research that targets the reduction of health disparities among children. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project duration is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





Reducing overscreening for breast, cervical and colorectal cancers among older adults (R01 clinical trial optional)

NIH: National Cancer Institute

This promotes research on intervention based in healthcare settings, designed to reduce overscreening for breast, cervical or colorectal cancers among average-risk older adults. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project duration is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Basic mechanisms of brain development mediating substance use and dependence (R01)

NIH: National Institute on Drug Abuse

This supports applications from investigators that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behaviour and in substance use and dependence. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R01 clinical trial optional)

NIH: National Institute of Mental Health

This encourages applications focused on advancing understanding of mechanisms by which mental health affects HIV, and developing and testing expanded interventions to improve both mental health and HIV outcomes. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The scope of the proposed project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Advancing our understanding of the brain epitranscriptomics (R01)

NIH: National Institute of Mental Health

This supports research into the functions of modified RNAs in the brain and in the associated modification proteins that act on RNA that play a role in basic neurobiological and behavioural processes implicated in mental and substance use disorders.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Cancer tissue engineering collaborative: enabling biomimetic tissue-engineered technologies for cancer research (R01)

NIH: National Cancer Institute

This supports the development and characterisation of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Budgets are limited to USD 400,000

direct costs per year. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

From genomic association to causation: a convergent neuroscience approach for integrating levels of analysis to delineate brain function in neuropsychiatry (U01)

NIH: National Institutes of Health

This aims to stimulate innovative convergent neuroscience approaches to establish causal or probabilistic linkages across contiguous levels of analysis in an explanatory model of psychopathology. Application budgets

may not exceed USD 2,500,000 direct cost annually for all applications combined in a collaborative set and are expected to reflect actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R01 clinical trial optional)

NIH: National Institute of Mental Health

This encourages implementation research projects designed in partnership with global and domestic service providers to achieve 90/90/90 goals for HIV/AIDS prevention and treatment. Application budgets are not limited but should reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Marijuana, prescription opioid or prescription benzodiazepine drug use among older adults (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. Application budgets are not limited but

need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Secondary analysis and integration of existing data to elucidate the genetic architecture of cancer risk and related outcomes (R01)

NIH: National Cancer Institute

This encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim of elucidating the genetic architecture of cancer risk and related outcomes. Application budgets

are limited to USD 350,000 in direct costs per year. The maximum project duration is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

From genomic association to causation – a convergent neuroscience approach for integrating levels of analysis to delineate brain function in neuropsychiatry (R01)

NIH: National Institute of Mental Health

This supports innovative convergent neuroscience approaches to establish causal or probabilistic linkages across contiguous levels of analysis in an explanatory model of psychopathology. Application budgets may not exceed

USD 500,000 per year. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Effectiveness trials for post-acute interventions and services to optimise longer-term outcomes (R01 clinical trial required)

NIH: National Institute of Mental Health

This supports research projects that evaluate the effectiveness of service delivery interventions for the post-acute management of mental health conditions affecting youth, adults and older adults. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Therapeutic strategies for the converging TB/T2DM/HIV epidemics (R01)

NIH: National Institute of Allergy and Infectious Diseases

This supports innovative research that improves the understanding of innate and adaptive immune dysregulation caused by type 2 diabetes mellitus and pre-diabetes that causes increased risk of tuberculosis in the context of HIV co-

infection. Application budgets are not limited but need to reflect the actual needs of the project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Discovery of small molecule immunomodulators for cancer therapy (R01)

NIH: National Cancer Institute

This promotes the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognise and attack cancer cells. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Using small molecules and molecular genetics to identify novel targets and mechanisms contributing to tumour immune evasion (R01)

NIH: National Cancer Institute

This aims to stimulate research on the identification of new and novel targets and mechanisms involved in tumour immune evasion, which may be amenable to analysis by small molecules, pharmacological, or molecular genetics approaches.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Synthetic biology for engineering (R01 clinical trial optional)

NIH: National Institute of Biomedical Imaging and Bioengineering

This supports research that advances the understanding and application of synthetic biology for human health. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum award project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Assay development and screening for discovery of chemical probes or therapeutic agents (R01)

NIH: National Cancer Institute

This supports research in discovery and development of novel, small molecules for their potential use in studying disease treatment, and to generate new insight into the biology of relevant diseases and processes. Application budgets are not limited but need to

reflect the actual needs of the proposed project, for a period of up to four years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Interplay of cell death pathways in cancer cell survival and resistance to therapy (R01)

NIH: National Cancer Institute

This supports basic and preclinical research in the interplay between cell death pathways in naïve and drug resistant cancers. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The total project period may not exceed five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Biology of lung, and head and neck preneoplasias (R01)

NIH: National Cancer Institute

This supports research investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck cancers. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Secondary analyses of existing alcohol research data (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports analysis of recently collected data and findings in alcohol epidemiology, prevention and genetic research with a focus on prenatal alcohol exposure. Application budgets

are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Understanding and modifying temporal dynamics of coordinated neural activity (R01 clinical trial optional)

NIH: National Institute of Mental Health

This supports research to lay the groundwork for developing systems-level neuroscience interventions into treatments for cognitive, affective or social deficits in psychiatric disorders. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Research on the health of transgender and gender nonconforming populations (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research on the health of transgender and gender nonconforming people of all ages. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Comparative genomics research programme (R01-clinical trial not allowed)

NIH: National Human Genome Research Institute

The National Human Genome Research Institute invites applications for its comparative genomics research programme. This supports development of new comparative genomics research approaches using genomic data types to understand biological systems,

networks and pathways. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

New onset depressive symptoms in acute illness (R01 clinical trial not allowed)

NIH: National Institute of Nursing Research

This encourages research on the aetiology of depressive symptoms that occur in the context of a sudden onset acute illness. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Addressing chronic wound trajectories through social genomics research (R01 – clinical trial optional)

NIH: National Institute of Nursing Research

This supports clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Implementing the most successful interventions to improve HIV/AIDS outcomes in US communities (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This supports projects that translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalised populations in the US with a substantial risk of HIV-infection and AIDS.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

SIREN neurologic clinical trials (U01 clinical trial required)

NIH: National Institute of Neurological Disorders and Stroke

This supports neurological clinical trials to be carried out in the Strategies to Innovate Emergency Care Clinical Trials Network, which aims to help provide robust and readily accessible infrastructure for the implementation of clinical trials in emergency indications

in the field of neurology. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Fundamental science research on mind and body approaches (R01 clinical trial optional)

NIH: National Center for Complementary and Integrative Health

This investigates the fundamental science of mind and body approaches, body-based approaches, meditative exercise, art and music therapies, or integrative approaches combining several components. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Investigator-initiated clinical trials targeting diseases within the mission of NIDDK (R01 clinical trial required)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports clinical trials to be conducted at no more than two clinical research centres. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



The application of big data analytics to drug abuse research (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This encourages the application of big data analytics to reveal deeper or novel insights into the biological and behavioural processes associated with

substance abuse and addiction. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Revision applications for validation of mobile or wireless health tools for measurement and intervention (R01 clinical trials not allowed)

NIH: National Institutes of Health

This invites revision applications from investigators and institutions or organisations with active NIH-supported R01 research project awards to support an expansion of the scope of approved and funded projects to incorporate recent advances in mobile

or wireless tools. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Revision applications for validation of mobile or wireless health tools for measurement and intervention (R01 clinical trial optional)

NIH: National Institutes of Health

This invites revision applications from investigators and institutions or organisations with active NIH-supported R01 research project awards to support an expansion of the scope of approved and funded projects to incorporate recent advances in mobile

or wireless tools. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Human subjects mechanistic and minimal risk studies (R01 clinical trial optional)

NIH: National Eye Institute

This encourages applications that seek to conduct studies of the visual system. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





NIDCD clinical trials in communication disorders (R01 clinical trial required)

NIH: National Institute on Deafness and other Communication Disorders

This supports investigator initiated low risk clinical trials addressing the mission and research interests of the National Institute on Deafness and Other Communication Disorders. Application budgets are limited to less

than USD 500,000 in direct costs in any year. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Population health interventions – integrating individual and group level evidence (R01 clinical trial optional)

NIH: National Cancer Institute

This supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



NIBIB research project grant (R01 clinical trial required)

NIH: National Institute of Biomedical Imaging and Bioengineering

This supports a discrete, specified, circumscribed project in areas related to the programmatic interests of the National Institute of Biomedical Imaging and Bioengineering. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



NICHD research project grant (R01 clinical trial required)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports clinical trials that fall within the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)





Research project grant (parent R01 clinical trial not allowed)

NIH: National Cancer Institute

This supports projects related to the programmatic interests of one or more of the participating NIH institutes and centres based on their scientific missions. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Using information technology to support systematic screening and treatment of depression in oncology practices (R01 clinical trial optional)

NIH: National Cancer Institute

This aims to identify new, IT-enabled delivery models that support systematic screening and treatment of depression in cancer patients. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

End-of-life and palliative care health literacy – improving outcomes in serious, advanced illness (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care health literacy in diverse settings and populations. Application budgets are not limited but should reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Alzheimer's clinical trials consortium clinical trials (R01 clinical trial required)

NIH: National Institute on Aging

This supports the development and implementation of phase I to III clinical trials of pharmacological and non-pharmacological interventions that may prevent, delay, or treat Alzheimer's disease. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Cancer prevention and control clinical trials grant programme (R01 clinical trial required)

NIH: National Cancer Institute

This supports investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, or survivorship related to cancer. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Investigator-initiated early phase clinical trials for cancer treatment and diagnosis (R01 clinical trial required)

NIH: National Cancer Institute

This supports projects that implement early phase investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions. Application budgets are limited to less than USD 500,000 in

direct costs per year. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Traceback testing – increasing identification and genetic counselling of mutation carriers through family-based outreach (U01 clinical trial optional)

NIH: National Cancer Institute

This supports pilot research projects using a traceback approach to genetic testing women with a personal or family history of ovarian cancer. Application budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is four years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Understanding processes of recovery in the treatment of alcohol use disorder (R01 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports the examination of processes of recovery and relapse in the treatment of alcohol use disorders. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Mechanistic investigations of psychosocial stress effects on opioid use patterns (R01 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports research to characterise the consequences of psychosocial stress on affective and cognitive functioning, or pain processing as it relates to opioid use disorder. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Disease mechanisms of prenatal and paediatric hydrocephalus (R01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports hypothesis-driven research of prenatal and paediatric hydrocephalus. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Genetics of alcohol sensitivity and tolerance (R01 clinical trial not allowed)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports efforts on identifying genetic, genomic and epigenetic factors contributing to the development of sensitivity and tolerance to alcohol. Funding is for five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Developmental pharmacodynamics and models of drug effects in paediatrics (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports multidisciplinary, investigator-initiated studies to increase and establish data on developmental pharmacodynamics in

the paediatric age groups. Funding is for five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Innovative therapies and tools for screenable disorders in newborns (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been

identified through newborn screening. Funding is for five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

High priority HIV/AIDS research within the mission of the NIDDK (R01 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports basic, translational and clinical research on diabetes and other endocrine and metabolic diseases that also addresses high priority HIV/AIDS research priorities and aims to improve

people's health and quality of life. Funding is for five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Basic and translational oral health research related to HIV/AIDS (R01 clinical trial not allowed)

NIH: National Institute of Dental and Craniofacial Research

This supports innovative and basic translational research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity. Funding is for five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Improving patient adherence to treatment and prevention regimens to promote health (R01 clinical trial optional)

NIH: Office of the Director

This supports research that addresses patient adherence to treatment and prevention regimens to promote health outcomes. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Generating new insights and mechanistic understanding of antibiotic resistance development (R01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease. Application budgets are not limited but must reflect the

actual needs of the project. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Accelerating basic and translational research in hidradenitis suppurativa (R01 clinical trial not allowed)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

This supports basic and translational studies to understand the aetiology and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic and immunologic factors, causing or associated with

hidradenitis suppurativa. Grants are worth up to USD 500,000 per year for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Age-related microbiota changes and their implications in chronic disease prevention, treatment and progression (R01 clinical trial optional)

NIH: National Cancer Institute

This supports the assessment of the role of the microbiome in health and disease during ageing. Applications budgets are not limited but should reflect the actual

needs of the proposed project for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Innovative mental health services research not involving clinical trials (R01)

NIH: National Institute of Mental Health

This supports innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. Application budgets are not limited but

need to reflect the actual needs of the proposed project. Funding is for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Identification and management of behavioural symptoms and mental health conditions in individuals with intellectual disabilities (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research to identify and manage behavioural symptoms and mental health conditions in individuals with intellectual disabilities. Applications budgets are not limited but must reflect the actual needs of the

proposed project, The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Precision imaging of oral lesions (R01 clinical trial not allowed)

NIH: National Institute of Dental and Craniofacial Research

This supports the development, adaptation, optimisation and validation of accurate, reproducible, specific and sensitive imaging approaches to improve diagnosis, treatment and treatment monitoring for diseases and

conditions in the oral cavity and oropharynx. Funding is for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Analyses of CALERIE data and biospecimens to elucidate mechanisms of caloric restriction-induced effects in humans (R01 clinical trial not allowed)

NIH: National Institute on Aging

This supports analyses of data from the comprehensive assessment of long-term effects of reducing intake of energy trial in order to better understand the effects of caloric restriction on risk factors for chronic diseases, as well as the cellular and molecular mechanisms mediating

the effects of sustained caloric restriction in humans. Funding is for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Analyses of adherence strategies and datasets from CALERIE to explore behavioural and psychosocial aspects of sustained caloric restriction in humans (R01 clinical trial not allowed)

NIH: National Institute on Aging

This supports secondary analyses of data from the comprehensive assessment of long-term effects of reducing intake of energy trial to explore behavioural and psychosocial aspects of sustained caloric restriction in humans, including the translation of

the caloric restriction adherence strategies to promote health behaviours. Funding is for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research related to the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal, hypothalamo-pituitary-adrenal and hypothalamo-pituitary-thyroid axes in

the brain. Budgets are limited to USD 499,999 in direct costs per year for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Advancing research needed to develop a universal influenza vaccine (R01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports research that will advance the development a universal influenza vaccine providing durable protection against multiple influenza strains. Application budgets are not limited but need to reflect the actual

needs of the project. Funding is for up to five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R01 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of alcohol or

drugs singly or in combination. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Novel approaches for relating genetic variation to function and disease (R01 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports the development of novel and generalisable approaches to study how genetic variants lead to differences in function, how such functional differences affect human health and disease processes or how this

knowledge can be used clinically. Funding is for up to four years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)



Advancing translational and clinical probiotic/prebiotic and human microbiome research (R01 clinical trial optional)

NIH: National Cancer Institute

This supports translational and clinical studies using a variety of probiotic and prebiotic carriers to generate measurable functional evidence for the safe and effective use of these carriers in maintaining health or preventing and

treating diseases. The maximum project period is five years.

Closing date: 05 Oct 18

[Link to *Research Professional](#)

Sleep disorders and circadian clock disruption in Alzheimer's disease and other dementias of ageing (R01 clinical trial not allowed)

NIH: National Institute on Aging

This supports molecular, cellular, genetic, epigenetic and systems biology approaches to advance basic and clinical research on the causes and consequences of sleep deficiency and circadian clock dysfunction in Alzheimer's disease. Application

budgets are limited to USD 500,000 in direct costs per year. The maximum project period is five years.

Closing date: 07 Oct 18

[Link to *Research Professional](#)

Building evidence: effective palliative/end of life care interventions (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks to stimulate research that tests optimal end-of-life and palliative care interventions or models of care that are based on individual- and family-centred outcomes. Application budgets are not limited, but must reflect

the actual needs of the project. The maximum project period is five years.

Closing date: 08 Oct 18

[Link to *Research Professional](#)

Human cell biology of genetic variants in Alzheimer's disease (R01 clinical trial not allowed)

NIH: National Institute on Aging

This aims to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimer's disease, in neural cells using human induced pluripotent stem cells. A budget of USD 6 million is

available in fiscal year 2018 to fund seven to nine awards. The maximum project period is five years.

Closing date: 09 Oct 18

[Link to *Research Professional](#)



BRAIN initiative – development of novel tools to probe cell-specific and circuit-specific processes in human and non-human primate brain (UG3/UH3 clinical trial optional)

NIH: National Institute of Mental Health

This supports the development and validation of novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. The total budget is USD 10 million to fund

six to nine awards. The maximum project period is five years.

Closing date: 09 Oct 18

[**Link to *Research Professional**](#)



Leveraging cognitive neuroscience to improve assessment of cancer treatment-related cognitive impairment (R21 clinical trial optional)

NIH: National Cancer Institute

This encourages transdisciplinary research that leverages cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. Grants are

worth USD 275,000 each for up to two years.

Closing date: 10 Oct 18

[**Link to *Research Professional**](#)



Leveraging cognitive neuroscience to improve assessment of cancer treatment-related cognitive impairment (R01 clinical trial optional)

NIH: National Cancer Institute

This encourages transdisciplinary research that leverages cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often

referred to as chemobrain. The maximum project period is five years.

Closing date: 10 Oct 18

[**Link to *Research Professional**](#)



Predicting behavioural responses to population-level cancer control strategies (R21 clinical trial optional)

NIH: National Cancer Institute

This supports research that identifies individual influences on the effectiveness of population-level strategies that target cancer-related behaviours. The combined budget for

direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 10 Oct 18

[**Link to *Research Professional**](#)





Fundamental mechanisms of affective and decisional processes in cancer control (R01 clinical trial optional)

NIH: National Cancer Institute

This supports projects aiming to generate fundamental knowledge of affective processes in cancer control. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 10 Oct 18

[Link to *Research Professional](#)

Early phase clinical trials in imaging and image-guided interventions (R01 clinical trial required)

NIH: National Cancer Institute

This supports clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning or execution therapy, contrast kinetic modelling, 3D reconstruction and other

quantitative tools. Grants are worth up to USD 500,000 for up to three years

Closing date: 11 Oct 18

[Link to *Research Professional](#)

Improving smoking cessation in socioeconomically disadvantaged populations via scalable interventions (R01 clinical trial optional)

NIH: National Cancer Institute

This supports innovative intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations. Application budgets are

not limited but need to reflect the actual needs of the proposed project.

Closing date: 11 Oct 18

[Link to *Research Professional](#)

Improving smoking cessation in socioeconomically disadvantaged populations via scalable interventions (R21 clinical trial optional)

NIH: National Cancer Institute

This supports highly innovative and promising intervention research designed to improve smoking cessation outcomes among socio-economically disadvantaged populations. Application budgets are limited to USD 275,000

over a two-year period with no more than USD 200,000 in direct costs allowed in any single year.

Closing date: 11 Oct 18

[Link to *Research Professional](#)



Single-site investigator-initiated clinical trials (R61/R33: clinical trial required)

NIH: National Heart, Lung and Blood Institute

This supports development and implementation of phase II and beyond investigator-initiated single-site clinical trials relevant to the research mission of the National Heart, Lung and Blood Institute. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 11 Oct 18

[Link to *Research Professional](#)



Clinical coordinating centre for multi-site investigator-initiated clinical trials (collaborative UG3/UH3 clinical trial required)

NIH: National Heart, Lung and Blood Institute

This supports the development and implementation of a clinical coordinating centre for investigator-initiated multi-site phase II and beyond clinical trials that are relevant to the research mission of the National Heart, Lung and Blood Institute. Application

budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 11 Oct 18

[Link to *Research Professional](#)



Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required)

NIH: National Heart, Lung and Blood Institute

This supports the implementation of a collaborating data coordinating centre for investigator-initiated multi-site phase II and beyond clinical trials that are relevant to the research mission of the National Heart, Lung, and Blood

Institute. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 11 Oct 18

[Link to *Research Professional](#)



Development of psychosocial therapeutic and preventive interventions for mental disorders (R61/R33 clinical trial required)

NIH: National Institute of Mental Health

This supports efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Applications budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum combined project period is five years.

Closing date: 15 Oct 18

[Link to *Research Professional](#)





Development of psychosocial therapeutic and preventive interventions for mental disorders (R33 clinical trial required)

NIH: National Institute of Mental Health

This supports the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is three years.

Closing date: 15 Oct 18

[Link to *Research Professional](#)



Clinical trials to test the effectiveness of treatment, preventive, and services interventions (R01 clinical trial required)

NIH: National Institute of Mental Health

This supports clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators and mechanisms of action of these interventions. Applications budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years but a three to four year period is highly preferred.

Closing date: 15 Oct 18

[Link to *Research Professional](#)



Clinical trials to test the effectiveness of treatment, preventive, and services interventions (collaborative R01 clinical trial required)

NIH: National Institute of Mental Health

This supports clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators and mechanisms of action of these interventions. Applications budgets are not limited but need to reflect the actual needs of the proposed

project. The maximum project period is five years but a three to four year period is highly preferred.

Closing date: 15 Oct 18

[Link to *Research Professional](#)



Pilot effectiveness trials for treatment, preventive and services interventions (R34 clinical trial required)

NIH: National Institute of Mental Health

This supports effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings and research on the development and preliminary testing of innovative

services interventions. Application budgets are worth up to USD 450,000 over a three-year period. No more than USD 225,000 may be requested in any single year.

Closing date: 15 Oct 18

[Link to *Research Professional](#)





Administrative supplements for research on dietary supplements (admin supp clinical trial not allowed)

NIH: National Institutes of Health

This supports research in which the supplemental funding would investigate the role of dietary supplements or their ingredients in health maintenance and disease prevention. Application budgets are limited to USD 100,000 and must

not exceed the amount of the current parent award.

Closing date: 15 Oct 18

[Link to *Research Professional](#)

Confirmatory efficacy clinical trials of non-pharmacological interventions for mental disorders (R01 clinical trial required)

NIH: National Institute of Mental Health

This supports confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 15 Oct 18

[Link to *Research Professional](#)

Prevention research in mid-life adults (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This supports research on mid-life adults, between 50 and 64 years of age, that can inform efforts to optimise health and wellness as individuals age, and prevent illness and disability in

later years. Funding is for up to five years.

Closing date: 15 Oct 18

[Link to *Research Professional](#)

Programme to assess the rigour and reproducibility of exosome- derived analytes for cancer detection (R21)

NIH: National Cancer Institute

This supports research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. Application

budgets are limited to US\$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.

Closing date: 15 Oct 18

[Link to *Research Professional](#)



Programme to assess the rigour and reproducibility of exosome-derived analytes for cancer detection (R01)

NIH: National Cancer Institute

This supports research projects that focus on innovative research in the isolation and characterisation of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 15 Oct 18

[Link to *Research Professional](#)

Early stage testing of pharmacologic or device-based interventions for the treatment of mental disorders (R33 clinical trial required)

NIH: National Institute of Mental Health

This supports early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is three years.

Closing date: 15 Oct 18

[Link to *Research Professional](#)

Early stage testing of pharmacologic or device-based interventions for the treatment of mental disorders (R61/R33 clinical trial required)

NIH: National Institute of Mental Health

This supports the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 15 Oct 18

[Link to *Research Professional](#)

Immune response to arthropod blood feeding (R21 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports short-term exploratory, developmental and transdisciplinary research to understand the immunologic events that occur during blood feeding by haematophagous

arthropods. Funding is worth up to USD 275,000 per project for up to two years.

Closing date: 15 Oct 18

[Link to *Research Professional](#)



Ensuring high quality in mentor mother strategy implementation – helping mothers eliminate paediatric HIV in Mozambique

Centers for Disease Control and Prevention (CDC)

This enables the recipient to provide technical assistance to Mozambique's Ministry of Health prevention of mother to child transmission programme, and to provincial health authorities and partners supporting HIV-exposed

infants. The grant is worth up to USD 5 million for one year.

Closing date: 15 Oct 18

[Link to *Research Professional](#)

NEI research grant for vision related secondary data analysis (R21)

NIH: National Eye Institute

This announcement encourages applications that propose to conduct vision-related secondary data analyses utilising existing database resources. Application budgets are limited to US\$275,000 for a maximum period of

two years. No more than US\$200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Imaging – science track award for research transition (R03 clinical trial optional)

NIH: National Institute on Drug Abuse

This facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to conduct small proof of concept

studies. The award covers direct costs of up to USD 150,000 for a maximum project period of one year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Exploratory or developmental research grant programme (parent R21 clinical trial not allowed)

NIH: National Eye Institute

This supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Application budgets are limited to USD

275,000 for a two-year period, with no more than USD 200,000 in any year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Pilot and feasibility clinical research grants in urologic disorders (R21 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports projects that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Grants are

worth up to USD 275,000 each over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Secondary analyses in obesity, diabetes, digestive and kidney diseases (R21 clinical trial not allowed)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports projects that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases, genetic metabolic disease, obesity, liver diseases, alimentary gastrointestinal tract diseases, kidney,

urological, and haematological diseases. Application budgets are limited to USD 275,000 over a two-year period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Health promotion among racial and ethnic minority males (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate and expand research in the health of minority men. Application budgets are limited to USD 275,000 for the two-year project period,

with no more than USD 200,000 available in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Small research grants for oral health data analysis and statistical methodology development (R03)

NIH: National Institute of Dental and Craniofacial Research

This announcement supports research projects that involve secondary data analyses of existing oral or craniofacial database resources, or aims to develop needed statistical methodology for analysing oral and craniofacial data using existing oral or craniofacial

databases. Projects may receive up to US\$100,000 per year for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Small research grant programme (parent R03 clinical trial not allowed)

NIH: National Institute of Nursing Research

This supports small research projects that can be carried out in a short period of time with limited resources.

Application budgets are limited to USD

50,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Mechanisms of alcohol-associated cancers (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research investigating the cellular and molecular mechanisms by which alcohol increases cancer risk. The combined budget for direct costs for the two year project period may not exceed USD 275,000. No more than USD

200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Prescription drug abuse (R21 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to develop innovative research on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse and to develop effective prevention and service delivery approaches and behavioural and pharmacological treatments.

Application budgets are limited to USD 275,000 over a two-year period. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Research on autism spectrum disorders (R03 clinical trial optional)

NIH: National Institute of Mental Health

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders. Direct costs

are limited to USD 100,000 over a two-year project period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Research on autism spectrum disorders (R21 clinical trial optional)

NIH: National Institute of Mental Health

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders. Application

budgets are limited to USD 275,000 for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Pilot and feasibility clinical trials in diabetes, and endocrine and metabolic diseases (R21 clinical trial required)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports pilot and feasibility trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention or treatment of diabetes or selected endocrine and genetic metabolic diseases. Application

budgets are limited to USD 275,000 in direct costs over up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Exploratory/developmental bioengineering research grants (R21 clinical trial optional)

NIH: National Cancer Institute

This establishes the feasibility of technologies, techniques or methods that explore a unique multidisciplinary approach to a biomedical challenge, are high-risk but have high impact, and develop data that may lead to significant future research. Direct costs are limited

to USD 275,000 over a two-year period, with no more than USD 200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Behavioural and integrative treatment development programme (R03 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to encourage investigators to propose well-defined projects within the domain of behavioural or integrated interventions that can be completed within two years. Application budgets

are limited to USD 100,000 over a two-year period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Mechanisms, models, measurement and management in pain research (R21 clinical trial optional)

NIH: National Cancer Institute

This announcement aims to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these institutes and centres. Applications budgets are limited to USD 275,000 in direct costs

for a maximum period of two years. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Drug discovery for nervous system disorders (R21)

NIH: National Institute of Mental Health

This announcement aims to stimulate the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. Application budgets are limited to US\$275,000 over two years,

with no more than US\$200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Chronic condition self-management in children and adolescents (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages exploratory or developmental research that aims to improve self-management and quality of life in children and adolescents with chronic conditions. Application budgets are limited to USD 275,000 in direct

costs over two years, with no more than USD 200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Functional genetics, epigenetics and non-coding RNAs in substance use disorders (R21)

NIH: National Institute on Drug Abuse

This announcement encourages basic functional genomic research that identifies genes and gene variants that may impact the fundamental biological mechanisms underpinning substance

use disorders. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Alcohol use disorders: treatment, services and recovery research (R03 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on behavioural and pharmacological treatment for alcohol use disorders; organisational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from

alcohol use disorders. Direct costs are limited to USD 100,000 over a two-year period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Women and sex or gender differences in drug and alcohol abuse or dependence (R03 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This aims to advance identification of male-female differences in drug and alcohol research outcomes and to advance research specific to women or highly relevant to women. Grants are

worth up to USD 50,000 each per year over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Women and sex/gender differences in drug and alcohol abuse/dependence (R21 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to advance identification of male-females differences in drug and alcohol research outcomes, to uncover the mechanisms and to conduct translational research on these differences, and to advance research specific to women. The combined

budget for direct costs for the two-year project period may not exceed USD 275,000. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Development of animal models and related biological materials for research (R21)

NIH: Office of the Director

This announcement solicits proposals to develop, characterise or improve animal models and related biological materials for human health and disease or to improve diagnosis and control of diseases that might interfere with animal use for biomedical research purposes. Application budgets are

limited to US\$275,000 in direct costs over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Reducing health disparities among minority and underserved children (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages research that targets the reduction of health disparities among children. Application budgets are limited to USD 275,000 over a two-

year period. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Nutrition and alcohol-related health outcomes (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on associations between nutrition and alcohol-related health outcomes in humans and animal models. Grants are worth up to USD

50,000 per year over a maximum of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Nutrition and alcohol-related health outcomes (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The combined budget for direct costs for the two-year project period may not exceed

USD 275,000. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Screening and brief alcohol interventions in underage and young adult populations (R21 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on screening and brief interventions to prevent or reduce alcohol use and alcohol related harms among underage and young adult populations. Application budgets are worth up to USD 275,000 for a

maximum two-year period. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Small grant programme for new investigators (R03)

NIH: National Institute of Dental and Craniofacial Research

This supports pilot and developmental research with the intention of facilitating subsequent submission of an Individual research project grant (R01) application. Budgets for direct costs of

up to US\$150,000 over a two-year period may be requested.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Public policy effects on alcohol-, marijuana-, and other substance-related behaviours and outcomes (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This funding opportunity announcement encourages research on the effects of public policies on health-related behaviours and outcomes associated with alcohol, marijuana, and other substances. Direct costs are

limited to USD 275,000 over an R21 two-year period, with no more than USD 200,000 allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Public policy effects on alcohol-, marijuana-, and other substance-related behaviours and outcomes (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This funding opportunity announcement encourages applications to conduct research on the effects of public policies on health-related behaviours and outcomes associated with alcohol, marijuana, and other substances. Direct costs of up to USD

50,000 per year will be funded, with a total project period of a maximum of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Epidemiology and prevention in alcohol research (R21 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research investigating the epidemiology of alcohol use, alcohol-related harms and alcohol use disorders, and the prevention of underage drinking, alcohol-related harms and alcohol use disorders. Direct

costs are limited to USD 275,000 over a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Epidemiology and prevention in alcohol research (R03 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders.

Application budgets are limited to USD 50,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Alcohol use disorders – treatment, services and recovery research (R21 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on behavioural and pharmacological treatment for alcohol use disorders; organisational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from

alcohol use disorders. Direct costs are limited to USD 275,000 over a period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Methodology and measurement in the behavioural and social sciences (R21 clinical trial optional)

NIH: Office of the Director

This supports applications aimed at improving and developing methodology in the behavioural and social sciences through innovations in research designs, measurement, data collection and data analysis techniques.

Application budgets are limited to USD 275,000 in direct costs, with no more

than USD 200,000 allowed in any single year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Research to advance vaccine safety (R21 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports research that will contribute to the overall understanding of vaccine safety. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Pilot and feasibility studies in preparation for drug and alcohol abuse prevention trials (R34 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports research that provides intervention pilot or feasibility data serving as a prerequisite for subsequent applications for larger scale drug or alcohol abuse prevention or drug- or alcohol-related HIV prevention

intervention studies. Grants are worth up to USD 450,000 each over three years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Diet and physical activity assessment methodology (R21 clinical trial not allowed)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports innovative research to enhance the quality of measurements of dietary intake and physical activity. Application budgets are limited to a

total of USD 275,000 in direct costs for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Behavioural and integrative treatment development programme (R34 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to encourage investigators to propose discrete well-defined projects within the domain of behavioural or integrated interventions that can be completed within three years.

Application budgets are limited to USD 450,000 over three years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

NEI clinical study planning grant programme (R34)

NIH: National Eye Institute

This announcement is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed manual of procedures. Application budgets are limited to

US\$150,000 in direct costs per year. The maximum period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Small research grants for data analysis and statistical methodology applied to genome-wide data (R03)

NIH: National Institute of Dental and Craniofacial Research

This supports meritorious research projects that involve statistical analysis of existing genome-wide data relevant to human dental, oral or craniofacial conditions or traits. Application budgets are limited to US\$200,000 over a

maximum project period of two years and no more than US\$200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Selected topics in transfusion medicine (R21 clinical trial optional)

NIH: National Heart, Lung and Blood Institute

This supports research on topics related to blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Application budgets are worth up to

USD 275,000 for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Multidisciplinary research in vulvodynia (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement aims to encourage new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are limited to US\$100,000 over the

maximum period of two years. No more than US\$50,000 in direct costs may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Multidisciplinary research in vulvodynia (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports new research applications in the exploration of etiology, prevention, diagnosis and therapeutics in the field of vulvodynia. Application budgets are limited to USD 275,000 over the maximum period of

two years. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Hearing health care for adults – improving access and affordability (R21 clinical trial optional)

NIH: National Institute on Deafness and other Communication Disorders

This supports research on hearing health care in adults in support of improving access and affordability. Direct costs are limited to USD 275,000 over a two-year project period, with no more than USD 200,000 in any single

year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Chemical discovery award (R21/R33)

NIH: National Institute on Drug Abuse

This supports the development of chemical probes that aid basic research investigations on substance use disorders or identify new lead chemical scaffolds with potential for structure activity relationship studies on SUDs. Direct costs are limited to USD 275,000 over a R21 two-year period, with a maximum of US\$200,000 allowed in any

single year. The R33 award phase will be limited to USD 250,000 in direct costs per year for a maximum period of three years. The total project period may not exceed four years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Ethical, legal and social implications of genomics research exploratory/developmental research programme (R21)

NIH: National Human Genome Research Institute

This supports studies on the ethical, legal and social implications of human genome research. Application budgets are limited to USD 275,000 in direct costs for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Cellular and molecular biology of complex brain disorders (R21)

NIH: National Institute of Mental Health

This encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. Application budgets are not

limited but must reflect the actual needs of the proposed project. The total project period may not exceed two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Development of appropriate paediatric formulations and paediatric drug delivery systems (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Application budgets are limited to USD 50,000 per

year in direct costs. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Development of appropriate paediatric formulations and paediatric drug delivery systems (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Application budgets are limited to USD 275,000

over a two-year project period, with no more than USD 200,000 in direct costs per year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages research to identify mechanisms of promoting positive sustainable health behaviour in children and youth up to the age of 18. The combined budget for the project may

not exceed USD 275,000. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Biomarkers: bridging paediatric and adult therapeutics (R21)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This encourages research that adapts adult biomarkers to children. Application budgets are limited to USD 275,000 in direct costs for a maximum project duration of two years. No more

than USD 200,000 may be requested in a single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate research utilising mobile health tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. The combined budget for direct costs for the two-year project

period may not exceed USD 275,000. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Health of sexual and gender minority populations (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research that will increase scientific understanding of the health status of sexual and gender minority population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Grants

are worth up to USD 275,000 over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse (R34 clinical trial optional)

NIH: National Institute on Drug Abuse

This encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Grants are worth up to USD 450,000 over three years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Environmental exposures and health: exploration of non-traditional settings (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities in non-traditional settings where exposure to environmental pollutants and toxins may occur. Application

budgets are limited to USD 275,000 in direct costs over a two-year project period, with no more than USD 200,000 in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Multidisciplinary studies of HIV/AIDS and ageing (R21 clinical trial optional)

NIH: National Institute on Aging

This supports studies that aim to improve understanding of aspects of ageing through the lens of HIV infection and its treatment, as well as improve approaches for testing of HIV infection and management of HIV-related

complications in different populations and cultural settings. Combined budgets are worth up to USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Physical activity and weight control interventions among cancer survivors – effects on biomarkers of prognosis and survival (R21 clinical trial optional)

NIH: National Cancer Institute

This supports transdisciplinary and translational research that will identify the specific biological or biobehavioural pathways through which physical activity or weight control may affect

cancer prognosis and survival. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Clinical development of minimally invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R21 clinical trial optional)

NIH: National Institute on Drug Abuse

This funding opportunity announcement solicits proposals that seek to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. Application budgets are

limited to USD 275,000 over a two-year period with no more than USD 200,000 per year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Examination of survivorship care planning efficacy and impact (R21 clinical trial optional)

NIH: National Cancer Institute

This aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up

care for cancer survivors. Application budgets are limited to USD 275,000 per year for a maximum project period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Effects of in utero alcohol exposure on adult health and disease (R21 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Application budgets are limited to

USD 275,000 over a two-year project period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Dissemination and implementation research in health (R03)

NIH: National Institute of Mental Health

This supports research that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures and strategies to disseminate and implement evidence-based health behaviour change interventions, evidence-based prevention, early detection, diagnostic,

treatment and management, and quality of life improvement services into public health, clinical practice and community settings. Application budgets are limited to \$50,000 in direct costs per year for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Improvement of animal models for stem-cell-based regenerative medicine (R21)

NIH: Office of the Director

This announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. Application budgets are limited to US\$275,000 over a two-year period,

with no more than US\$200,000 in any year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Small research grants for secondary analysis of FaceBase data (R03)

NIH: National Institute of Dental and Craniofacial Research

These support research projects that conduct secondary data analyses of the FaceBase Consortium datasets relevant to craniofacial development, human craniofacial conditions or traits and animal models of those conditions.

Application budgets are worth up to US\$200,000 over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Research grants using the resources from the osteoarthritis initiative (R21 clinical trial not allowed)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

This encourages research focused on the use of the osteoarthritis initiative database, clinical data and images. Direct costs may not exceed USD 275,000 over a two-year project period,

with no more than USD 200,000 in any year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Advancing the science of geriatric palliative care (R21 clinical trial optional)

NIH: National Institute on Aging

This supports the development of new tools, methods and models focused on palliative care in geriatric populations. The combined budget for direct costs for the two-year project period may not exceed USD 275,000. No more than USD

200,000 may be requested in any single year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Secondary data analyses to explore the National Institute of Mental Health research domain criteria (R03)

NIH: National Institute of Mental Health

This supports secondary analyses of existing clinical research data sets to investigate constructs identified in the NIMH's research domain criteria initiative and to test novel hypotheses using the RDoC framework. No more than USD 50,000 in direct costs may be

requested in any single year. The total project period may not exceed 2 years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports research to deepen the knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment. The combined budget for

direct costs may not exceed USD 100,000 over two years and no more than USD 50,000 in direct costs may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports research on the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment. Applications

budgets are limited to USD 275,000 in direct costs for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Family-centred self-management of chronic conditions (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks to build on the science of family-centred self-management in chronic conditions. The combined budget may not exceed USD 275,000. No more than USD 200,000 may be

requested in any single year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Alcohol-induced effects on tissue injury and repair (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Application budgets are

limited to USD 275,000 over a two-year project period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Community partnerships to advance research (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages researchers to partner with community groups, using community engaged research methodologies that will enhance relationships and lead to better intervention development and positive health outcomes. Application budgets

may not exceed USD 275,000 over two years and no more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Self-management for health in chronic conditions (R01 clinical trial optional)

NIH: National Institute of Nursing Research

This supports research in self-management for health in chronic conditions. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease- or age-related cognitive

decline. Grants are worth up to USD 275,000 over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Underactive bladder and detrusor activity in ageing (R21 clinical trial optional)

NIH: National Institute on Aging

This supports basic, clinical or translational research on underactive bladder and detrusor underactivity and its consequences in ageing and in older

persons. Grants are worth up to USD 275,000 each over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Underactive bladder and detrusor activity in ageing (R03 clinical trial optional)

NIH: National Institute on Aging

This supports basic, clinical or translational pilot or feasibility projects addressing underactive bladder and detrusor underactivity and its consequences in ageing and in older

persons. Grants are worth up to USD 100,000 each over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Prevention research in mid-life adults (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This supports research on mid-life adults, those between 50 and 64 years of age, that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. Grants are

worth up to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Early-life factors and cancer development later in life (R03 clinical trial not allowed)

NIH: National Cancer Institute

This stimulates research focused on the role of early-life factors in cancer development in later life. Awards are worth up to USD 100,000 each in direct

costs over a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Early-life factors and cancer development later in life (R21 clinical trial not allowed)

NIH: National Cancer Institute

This announcement stimulates research focused on the role of early-life factors in cancer development in later life. Awards are worth up to USD 275,000

each in direct costs over a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Pilot and feasibility clinical research grants in kidney diseases (R21 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney diseases research.

Grants are worth up to USD 275,000 each over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Immune system plasticity in the pathogenesis and treatment of complex dental, oral, and craniofacial diseases (R21)

NIH: National Institute of Dental and Craniofacial Research

This announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune

system. Application budgets are limited to a total of US\$275,000 in direct costs with up to US\$200,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Pilot services research grants not involving interventions (R34 clinical trial optional)

NIH: National Institute of Mental Health

This encourages pilot research consistent with the National Institute of Mental Health priorities for services research studies that are not immediate precursors to the development and testing of services interventions. Direct

costs are limited to USD 450,000 over the project period. The total project period may not exceed three years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Application budgets may not exceed

USD 275,000 over the maximum project period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Personalised strategies to manage symptoms of chronic illness (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness through increasing knowledge of the biological mechanisms of symptoms and promoting innovative, cost-effective, targeted interventions to prevent,

manage or ameliorate these symptoms. Grants are worth up to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Innovative questions in symptom science and genomics (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified questions in symptom and genomic nursing science. Application budgets are limited to USD 275,000 and

no more than USD 200,000 may be requested in any single year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Applying metabolomics to drive biomarker discovery in symptom science (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This encourages applications on biomarker discovery that utilise metabolomics approaches to advance the understanding, assessment and management of symptoms. The combined budget for direct costs excluding consortia facilities and

administration costs for the maximum two-year project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Advancing understanding, prevention, and management of infections transmitted from women to their infants (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This stimulates investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their

offspring. Grants are worth up to USD 275,000 in direct costs for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Improving outcomes in cancer treatment-related cardiotoxicity (R21 clinical trial optional)

NIH: National Cancer Institute

This supports collaborative projects that contribute to the identification and characterisation of patients at risk of developing cancer treatment-related cardiotoxicity. The total budget is worth up to USD 275,000 over a maximum period of two years. No more than USD

200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Education and health: new frontiers (R21 clinical trial optional)

NIH: National Cancer Institute

This supports research into the pathways involved in the relationship between education and health outcomes. Funding for the two year project period is worth up to USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Education and health: new frontiers (R03 clinical trial optional)

NIH: National Cancer Institute

This supports research that will further elucidate the pathways involved in the relationship between education and health outcomes. Application budgets are limited to USD 100,000 in direct costs over the maximum period of two

years. No more than USD 50,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Oocyte mitochondrial function in relation to fertility, ageing and mitochondrial diseases (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research in the area of oocyte mitochondrial function in relation to fertility, ageing and mitochondrial disease transmission to offspring. Application budgets are

limited to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Accelerating research on intervertebral disc (R21)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

This announcement encourages studies on basic biology of the intervertebral disc and seeks applications that accelerate an understanding of basic research on the intervertebral disc and develop new directions on the factors that lead to disc degeneration.

Application budgets are limited to US\$275,000 for the maximum period of two years. No more than US\$200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Zika virus complications (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This provides support for research on the Zika virus and its complications. Grants are worth up to USD 275,000 in direct costs over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Role of astrocytes and astrocytic networks in drug abuse (R21)

NIH: National Institute on Drug Abuse

This announcement aims to examine the effects of drugs of abuse on the structural connectivity of astrocytic networks within the central nervous system, and the generation, processing and spatiotemporal control of activities within these networks. Application budgets are limited to US\$275,000 in

direct costs over a maximum period of two years. No more than US\$200,000 in direct costs may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Population health interventions: integrating individual and group level evidence (R21 clinical trial not allowed)

NIH: Office of the Director

This supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. The combined budget for direct costs for the two year project

period may not exceed USD 275,000. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Tailoring dental treatment for individuals with systemic diseases that compromise oral health (R21)

NIH: National Institute of Dental and Craniofacial Research

This announcement aims to encourage developmental or exploratory clinical research related to addressing gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise

dental treatment guidelines tailored to patient needs. Application budgets are limited to US\$275,000 in direct costs over the maximum two year period. No more than US\$200,000 is allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

EXTENDED DEADLINE: Pilot and feasibility studies evaluating the role of ribonucleic acid modifications in cancer biology (R21)

NIH: National Cancer Institute

*** The National Cancer Institute has extended the expiration date for its pilot and feasibility studies evaluating the role of ribonucleic acid modifications in cancer biology (R21) funding opportunity announcement. The previous expiration date of 17 June 2019 has been extended to 17 July 2019. All other call information remain unchanged. This announcement encourages basic research into the role

of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer. Applications budgets are limited to US\$275,000 in direct costs over the maximum period of two years. No more than US\$200,000 may be requested in any single year. ***

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This aims to establish a programme of research to advance the understanding, prevention and treatment of paediatric multiple organ dysfunction syndrome. Application budgets are limited to USD

275,000 in direct costs for the maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Research to advance the understanding and management of the multiple organ dysfunction syndrome in children (R03 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This aims to advance the understanding, prevention and treatment of paediatric multiple organ dysfunction syndrome. Application budgets are limited to USD

50,000 in direct costs per year for the maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Role of mobile genetic elements in cancer (R21)

NIH: National Institutes of Health

This R21 funding opportunity announcement encourages applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements in cancer. Application budgets are limited to a total of

US\$275,000 in direct costs with a maximum of US\$200,00 in direct costs per year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Metabolic reprogramming to improve immunotherapy (R21)

NIH: National Cancer Institute

This announcement aims to generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, determine how the metabolic landscape of the tumour microenvironment affects immune effector functions, and then use this information to manipulate the metabolic pathways used by the

tumour, the immune response, or both to improve cancer immunotherapy. Application budgets are limited to US\$275,000 over a maximum period of two years. No more than US\$200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Non-healing ulcerative wounds in ageing (R21)

NIH: National Institute on Aging

This announcement seeks applications that propose basic, clinical, or translational research on non-healing ulcerative wounds and their consequences in ageing and in older persons. Application budgets are limited to US\$275,000 for a maximum

period of two years. No more than US\$200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Mechanisms mediating osteoarthritis in ageing (R21)

NIH: National Institute on Aging

This funding opportunity announcement encourages exploratory/development applications to accelerate the characterisation of new paradigms to test hypotheses that will lead to an improved understanding of the mechanisms of initiation and progression of osteoarthritis and the

role of the ageing process. Application budgets are limited to US\$275,000 direct cost funding for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Novel approaches to understanding, preventing and treating Lyme disease and tick-borne coinfections (R21)

NIH: National Institute of Allergy and Infectious Diseases

This R21 funding opportunity announcement supports research that will contribute to the overall understanding of Lyme disease and co-infections transmitted by Ixodes ticks. Direct costs are limited to US\$275,000

over a two-year period, with no more than US\$200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Gene fusion in paediatric sarcomas (R21)

NIH: National Cancer Institute

This R21 funding opportunity announcement encourages applications that explore the molecular biology of paediatric sarcomas to elucidate molecular mechanisms by which fusion genes and the resulting protein products drive tumorigenesis and

cancer progression. Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Mechanisms of cancer and treatment-related symptoms and toxicities (R21)

NIH: National Cancer Institute

This supports innovative pilot projects or feasibility studies to stimulate research aimed to better understand the complex interaction of biological, cognitive, behavioural and sociocultural factors that contribute to cancer and

treatment related symptoms and toxicities throughout the cancer care trajectory.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Stimulating innovations in behavioural intervention research for cancer prevention and control (R21 clinical trial optional)

NIH: National Cancer Institute

This supports the development of innovative interventions that improve cancer-related health behaviours across diverse racial or ethnic populations.

Application budgets are limited to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Integrative research on polysubstance abuse and addiction (R21/R33 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to characterise how the neurobiological alterations, associated behaviours, and public health consequences arising from polysubstance use differ from those observed in single drug use. The R21 phase is worth up to USD 275,000

during a two-year period, and the R33 phase is worth up to USD 500,000 per year for a three-year period. The total project period may not exceed five years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R21)

NIH: National Institute of Dental and Craniofacial Research

This supports exploratory or development research on mechanisms underlying the manifestations of sex-based differences in dental, oral and craniofacial related diseases and conditions. Application budgets are worth up to US\$275,000 in direct costs

for a two-year project period, with no more than US\$200,000 allowed for any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Factors underlying differences in female and male presentation for dental, oral and craniofacial diseases and conditions (R21): Aids-related

NIH: National Institute of Dental and Craniofacial Research

This Aids-related announcement supports exploratory or development research on mechanisms underlying the manifestations of sex-based differences in dental, oral and craniofacial related diseases and conditions. Application budgets are worth up to US\$275,000 in

direct costs for a two-year project period, with no more than US\$200,000 allowed for any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Characterisation of the adolescent reproductive transition (R03 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research in the area of puberty and the trajectory of sexual development. Application budgets are worth up to USD 50,000 in direct costs

per year for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Characterisation of the adolescent reproductive transition (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research in the area of puberty and the trajectory of sexual development. Application budgets are worth up to USD 275,000 for a maximum period of two years, with no

more than USD 200,000 allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Safety and outcome measures of pain medications used in children and pregnant women (R03 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications and develop effective instruments or approaches to evaluate maternal and

child outcomes of pain medication treatments. Grants are worth up to USD 50,000 per year for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Safety and outcome measures of pain medications used in children and pregnant women (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications and develop effective approaches to evaluate maternal and child outcomes

of pain medication treatments. Grants are worth up to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[**Link to *Research Professional**](#)



Small research grants for analyses of data for the Gabriella Miller Kids First Data Resource (R03 clinical trial not allowed)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports meritorious small research projects focused on the development and analyses of childhood cancer and structural birth defects datasets that are part of the Kids First Data Resource or could be included in it.

Funding is worth up to USD 200,000 for a maximum duration of two years.

Closing date: 16 Oct 18

[**Link to *Research Professional**](#)



Target assessment, engagement and data replicability to improve substance use disorders treatment outcomes (R33 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports data replication and the scalability of novel, targeted addiction treatments. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is three years.

Closing date: 16 Oct 18

[**Link to *Research Professional**](#)





Target assessment, engagement and data replicability to improve substance use disorders treatment outcomes (R21/R33 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports research that generates preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use. The two-year R21 phase may not exceed USD 275,000 in direct costs. In the three-

year R33 phase budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Phenotypic and functional characterisation of Apolipoprotein E two to inform translation strategies for ageing-related conditions (R21)

NIH: National Institute on Aging

This supports exploratory and developmental new research activities on ApoE2 and other variants to improve understanding of physiologic and cellular differences attributable to the ApoE e2 allele, versus other ApoE alleles, and how they mediate ApoE e2's

differential effects on longevity and risk for age-related conditions. Application budgets are worth up to US\$275,000 for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Secondary analyses of alcohol and chronic disease (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This announcement encourages research that uses existing datasets to examine associations between alcohol and non-communicable chronic diseases in order to facilitate innovative and cost-effective research using previously collected data. Application

budgets are limited to USD 50,000 in direct costs per year. The maximum project duration is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Symptom management in HIV-infected individuals with comorbid conditions (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks research applications focused on developing, adapting and testing innovative cost-effective strategies to prevent, identify and manage symptoms of HIV-associated Non-AIDS conditions and other

comorbidities among older adults with prolonged HIV infection. Grants are worth up to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Trophoblast differentiation and function (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research in the area of trophoblast differentiation and function in relation to fertility and pregnancy, including the role of the immune system. Grants are worth up to USD 275,000 over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Palliative care needs of individuals with rare advanced diseases and their family caregivers (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks to expand knowledge and increase the evidence base for palliative care in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Improving individual and family outcomes through continuity and coordination of care in hospice (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks to stimulate research that focuses on reducing negative individual and family outcomes related to unwanted transitions at the end of life and optimising the individual and family outcomes related to high quality coordination of care of individuals who

are enrolled in hospice. Application budgets are worth up to USD 275,000 for a two-year project period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Addressing unmet needs in persons with dementia to decrease behavioural symptoms and improve quality of life (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This aims to stimulate clinical research addressing behavioural and psychological symptoms of dementia and the association of BPSD with unmet physical, social or environmental needs in persons with dementia. Application

budgets are worth up to USD 275,000 for a two-year project period. No more than USD 200,000 in direct costs may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Self-management interventions and technologies to sustain health and optimise functional capabilities (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This supports clinical research on self-management interventions and technologies that improve health and quality of life in persons needing assistance to optimise and maintain existing functional capabilities, prevent or delay disabilities and navigate their

environment. Application budgets are worth up to USD 275,000 for a period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Use of technology to enhance patient outcomes and prevent illness (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This seeks clinical research focused on the development and utilisation of technologies that can help address patient outcomes. Application budgets are worth up to USD 275,000 for a two-year period. No more than USD 200,000

in direct costs may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Improving quality of care and quality of life for persons with Alzheimer's disease and related dementias at the end of life (R03)

NIH: National Institute on Aging

This seeks applications that propose analysis of secondary data, to address clinical and translational gaps in the study of end-of-life care needs of people with Alzheimer's disease or related dementias and their families.

Application budgets are worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Oral anticancer agents – utilisation, adherence and health care delivery (R21 clinical trial optional)

NIH: National Cancer Institute

This aims to assess and describe the current state of oral anticancer medication utilisation, delivery and adherence, identify structural, systemic, and psychosocial barriers to adherence and develop models and strategies to improve safe and effective delivery of

these agents so that clinical outcomes are optimised. Application budgets are worth up to USD 275,000 for a maximum two-year period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)





Exploratory analyses of existing cohorts, data sets and stored biospecimens to address clinical ageing research questions (R21)

NIH: National Institute on Aging

This supports studies employing secondary analysis of existing cohorts, data sets and biorepositories to explore clinically related issues on ageing changes influencing health across the lifespan, including diseases and disabilities in older persons. Application budgets are worth up to USD 275,000

for a maximum period of two years. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Fertility status as a marker for overall health (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports exploratory or developmental research that explores the premise that fertility status can be a marker for overall health. Grants are

worth up to USD 275,000 over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Reducing overscreening for breast, cervical and colorectal cancers among older adults (R21 clinical trial optional)

NIH: National Cancer Institute

This promotes research on intervention based in healthcare settings, designed to reduce overscreening for breast, cervical or colorectal cancers among average-risk older adults. Application

budgets are limited to USD 275,000 in direct costs over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Juvenile protective factors and their effects on ageing (R03)

NIH: National Institute on Aging

This call supports descriptive studies identifying putative juvenile protective factors, experimental studies testing hypotheses about their effects on ageing and translational studies exploring the potential risks and benefits of

maintaining or modulating the level of juvenile protective factors in adult life.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Innovations in mechanisms and interventions to address mental health in HIV prevention and care continuum (R21 clinical trial optional)

NIH: National Institute of Mental Health

This supports research focused on advancing understanding of mechanisms by which mental health affects HIV prevention and treatment in order to identify modifiable intervention targets; and developing and pilot testing expanded interventions to improve both mental

health and HIV outcomes. Application budgets are limited to USD 275,00 over the maximum combined period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Advancing our understanding of the brain epitranscriptome (R21)

NIH: National Institute of Mental Health

This supports research into the functions of modified RNAs in the brain and in the associated modification proteins that act on RNA that play a role in basic neurobiological and behavioural processes implicated in mental and substance use disorders.

Direct costs are limited to USD 275,000 over a two-year period, with no more than USD 200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Targeted implementation science to achieve 90/90/90 goals for HIV/AIDS prevention and treatment (R21 clinical trial optional)

NIH: National Institute of Mental Health

This encourages implementation research projects designed in partnership with global and domestic service providers to achieve 90/90/90 goals for HIV/AIDS prevention and treatment. Grants are worth up to USD

275,000 each for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Marijuana, prescription opioid or prescription benzodiazepine drug use among older adults (R21 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. Direct costs are limited to USD 275,000 over a two-year period, with no more than

USD 200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Marijuana, prescription opioid, or prescription benzodiazepine drug use among older adults (R03)

NIH: National Institute on Drug Abuse

This supports innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. Application budgets are limited to USD 50,000 in direct costs per year. The total

project period may not exceed two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Secondary analysis and integration of existing data to elucidate the genetic architecture of cancer risk and related outcomes (R21)

NIH: National Cancer Institute

This encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim of elucidating the genetic architecture of cancer risk and

related outcomes. Application budgets are limited to USD 275,000 in direct costs over a two-year project period, with no more than USD 200,000 allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

NICHD exploratory and developmental research grant (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports exploratory and developmental research projects in their early and conceptual stages. Direct costs are limited to USD 275,000 over a maximum period of two years, with no

more than USD 200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Pilot effectiveness trials for post-acute interventions and services to optimise longer-term outcomes (R34 clinical trial required)

NIH: National Institute of Mental Health

This supports pilot effectiveness projects that evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus.

Direct costs are limited to USD 450,000 over a period of up to three years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Therapeutic strategies for the converging TB/T2DM/HIV epidemics (R21)

NIH: National Institute of Allergy and Infectious Diseases

This supports innovative research that improves the understanding of innate and adaptive immune dysregulation caused by type 2 diabetes mellitus and pre-diabetes that causes increased risk of tuberculosis in the context of HIV co-

infection. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Small grants for secondary analyses of existing data sets and stored biospecimens (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research that conducts secondary analyses of publicly available data sets or stored biospecimens funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Application budgets are

limited to USD 50,000 in direct costs per year for a maximum performance period of up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Discovery of cell-based chemical probes for novel brain targets (R21)

NIH: National Institute of Mental Health

This supports investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets.

Application budgets are limited to USD 275,000 over a two-year period, with no

more than USD 200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Interplay of cell death pathways in cancer cell survival and resistance to therapy (R21)

NIH: National Cancer Institute

This supports basic and preclinical research in the interplay between cell death pathways in naïve and drug resistant cancers. Funding is worth up to USD 275,000 in direct costs over a two-year project period, with no more

than USD 200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



NIBIB exploratory/developmental research grant programme (R21 clinical trial optional)

NIH: National Institute of Biomedical Imaging and Bioengineering

This supports exploratory or developmental research projects of interest to the National Institute of Biomedical Imaging and Bioengineering, that will lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their

applications. Application budgets may not exceed USD 275,000 in direct costs over a maximum two-year funding period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Biology of lung, and head and neck preneoplasias (R21)

NIH: National Cancer Institute

This supports research investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck cancers. Direct costs are limited to USD 275,000 over a two-year project period, with no more than USD

200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Secondary analyses of existing alcohol research data (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports the secondary analysis of existing data sets with the goal of enhancing the understanding of patterns of alcohol consumption, the epidemiology and aetiology, including genetics, of alcohol-related problems.

Applications budgets are limited to USD 50,000 per year. The total project period may not exceed two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Understanding and modifying temporal dynamics of coordinated neural activity (R21 clinical trial optional)

NIH: National Institute of Mental Health

This supports projects that test whether modifying electrophysiological patterns during behaviour can improve cognitive, affective or social processing. The combined budget for direct costs

for the two-year project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Research on the health of transgender and gender nonconforming populations (R21 clinical trial optional)

NIH: National Cancer Institute

This supports research on the health of transgender and gender nonconforming people of all ages. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

New onset depressive symptoms in acute illness (R21 clinical trial not allowed)

NIH: National Institute of Nursing Research

This encourages research on the aetiology of depressive symptoms that occur in the context of a sudden onset acute illness. Application budgets are

limited to USD 275,000 over a two-year period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Implementing the most successful interventions to improve HIV/AIDS outcomes in US communities (R21 – clinical trial optional)

NIH: National Institute of Nursing Research

This supports implementation of interventions that demonstrate improved HIV-related health outcomes including HIV testing, pre-exposure prophylaxis and antiretroviral therapies adherence and sustained viral suppression in communities at risk in

the US. The combined budget for direct costs for the two-year project period is worth up to USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Addressing chronic wound trajectories through social genomics research (R21 – clinical trial optional)

NIH: National Institute of Nursing Research

This supports clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The combined budget for direct costs for the two-year project period may not exceed USD

275,000. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Fundamental science research on mind and body approaches (R21 clinical trial optional)

NIH: National Center for Complementary and Integrative Health

This investigates the fundamental science of mind and body approaches, body-based approaches, meditative exercise, art and music therapies, or integrative approaches combining several components. The combined budget for direct costs for the two-year

project period may not exceed USD 275,000. No more than USD 200,000 may be requested in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Exploratory or developmental research grant programme (Parent R21 clinical trial required)

NIH: National Human Genome Research Institute

This supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Direct costs are limited to USD 275,000 over a maximum period of two years,

with no more than USD 200,000 in direct costs allowed in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

NIMH exploratory/developmental research grant (R21 clinical trial not allowed)

NIH: National Institute of Mental Health

This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these

projects. Grants are worth up to USD 275,000 over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

NINDS exploratory neuroscience research grant (R21 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This supports exploratory and innovative research projects, which fall within the mission of the National Institute of Neurological Disorders and

Stroke. Grants are worth up to USD 275,000 for two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Stimulating innovations in behavioural intervention research for cancer prevention and control (R21 clinical trial optional)

NIH: National Cancer Institute

This supports the development of innovative interventions that improve cancer-related health behaviours across diverse racial and ethnic populations.

Direct costs are limited to USD 275,000 over a period of up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Population health interventions – integrating individual and group level evidence (R21 clinical trial optional)

NIH: National Cancer Institute

This supports multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes. Application budgets are

limited to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Feasibility clinical trials of mind and body interventions for NCCIH high priority research topics (R34 clinical trial required)

NIH: National Center for Complementary and Integrative Health

This supports early-phase clinical trials of mind and body approaches for conditions that have been identified by the National Center for Complementary and Integrative Health as high priority research topics. Application budgets are

limited to USD 450,000 for up to three years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

NICHD small grant programme (R03 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports small research projects that can be carried out in a short period of time with limited resources. Application budgets are limited to USD

50,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Using information technology to support systematic screening and treatment of depression in oncology practices (R21 clinical trial optional)

NIH: National Cancer Institute

This aims to identify new, IT-enabled delivery models that support systematic screening and treatment of depression in cancer patients. The combined budget for direct costs for the two-year

project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Human subjects mechanistic and minimal risk studies (R21 clinical trial optional)

NIH: National Eye Institute

This supports low-risk studies of the visual system. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

End-of-life and palliative care health literacy: improving outcomes in serious, advanced illness (R21 clinical trial optional)

NIH: National Institute of Nursing Research

This stimulates research focused on identification of the key barriers to effective end-of-life and palliative care health literacy in diverse settings and

populations. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Pilot and feasibility studies of HIV and animal models for HIV infection within the mission of the NIDDK (R21 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports basic and translational research projects examining HIV infection, persistence, and comorbidities relevant to the the institute's study of diabetes and other endocrine and metabolic diseases, digestive diseases, nutritional disorders, obesity, and kidney, urologic and

haematologic diseases. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Understanding processes of recovery in the treatment of alcohol use disorder (R21 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports examination of processes of recovery and relapse in the treatment of alcohol use disorders. Application budgets are limited to USD 200,000 in

direct costs per year. The maximum project period is two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

NIDA small research grant programme (R03 clinical trial required)

NIH: National Institute on Drug Abuse

This supports small research projects that can be carried out in a short period of time with limited resources.

Application budgets are limited to USD 50,000 in direct costs per year. The total

project period may not exceed two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports innovative research characterising the consequences of psychosocial stress on affective and cognitive functioning and pain processing as it relates to opioid use disorder. The combined budget for

direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Tools to enhance the study of prenatal and paediatric hydrocephalus (R21 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports research that develops or substantially modifies existing cutting-edge tools that will advance prenatal or paediatric hydrocephalus research.

Funding is worth up to USD 275,000 over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Mechanisms of alcohol tolerance (R21/R33 clinical trial not allowed)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports the study of sensitivity and tolerance mechanisms underlying the development of alcohol use disorders. The award is worth up to USD 1.77 million for up to five years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Developmental pharmacodynamics and models of drug effects in paediatrics (R03 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports multidisciplinary basic translational and clinical research to increase and establish data on developmental pharmacodynamic in the paediatric age groups and to determine pharmacokinetic-pharmacodynamic relationships of drugs used in this

relationship. Grants are worth up to USD 50,000 per year for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Innovative therapies and tools for screenable disorders in newborns (R03 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as high priority genetic conditions where screening may be

possible in the near future. Grants are worth up to USD 100,000 each over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Innovative therapies and tools for screenable disorders in newborns (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening.

Grants are worth up to USD 275,000 each over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Basic and translational oral health research related to HIV/AIDS (R21 clinical trial not allowed)

NIH: National Institute of Dental and Craniofacial Research

This supports basic and translational exploratory research into mechanisms of HIV transmission, persistence, pathogenesis and co-morbidities in the oral cavity. Application budgets are

limited to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Improving patient adherence to treatment and prevention regimens to promote health (R21 clinical trial optional)

NIH: Office of the Director

This supports research that addresses patient adherence to treatment and prevention regimens to promote health outcomes. Grants are worth up to USD 275,000 for a two-year period, with no

more than USD 200,000 in any single year.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Generating new insights and mechanistic understanding of antibiotic resistance development (R21 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease. Application budgets

are limited to USD 275,000 for a two-year period.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Small research grants for establishing basic science-clinical collaborations to understand structural birth defects (R03 clinical trial not allowed)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

These promote the initial establishment of basic science-clinical collaboration by providing small grants to teams of basic scientists, physician scientists or

clinicians. Grants are worth up to USD 75,000 per year for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Accelerating basic and translational research in hidradenitis suppurativa (R21 clinical trial not allowed)

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

This supports high risk and high reward basic and translational studies aimed at understanding the aetiology and the cellular and molecular mechanisms causing or associated with hidradenitis

suppurativa. Grants are worth up to USD 275,000 each over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Age-related microbiota changes and their implications in chronic disease prevention, treatment and progression (R21 clinical trial optional)

NIH: National Cancer Institute

This supports the assessment of the role of the microbiome in health and disease during ageing. Grants are worth up to USD 275,000 for two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

In vivo synaptic function in Alzheimer's disease and related dementias (R21 clinical trial not allowed)

NIH: National Institute on Aging

This supports the study of in vivo synaptic structure and function in Alzheimer's and related dementias and aims to advance development of methods to study synapses in animal

models and humans. Grants are worth up to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Precision imaging of oral lesions (R21 clinical trial not allowed)

NIH: National Institute of Dental and Craniofacial Research

This supports early-stage research projects that propose to adapt, optimise and validate existing imaging systems or develop new image-based methodologies and analytic tools capable of improving early detection, diagnosis and targeted treatment of oral

diseases and conditions. Grants are worth up to USD 275,000 each over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Exploratory analyses of CALERIE data and biospecimens to elucidate mechanisms of caloric restriction-induced effects in humans (R21 clinical trial not allowed)

NIH: National Institute on Aging

This supports analyses that will lead to a more detailed understanding of the effects of caloric restriction on risk factors for chronic diseases and the cellular and molecular mechanisms mediating the effects of sustained

caloric restriction in humans. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Exploratory analyses of adherence strategies and data sets from CALERIE to investigate behavioural and psychosocial aspects of sustained caloric restriction in humans (R21 clinical trial not allowed)

NIH: National Institute on Aging

This supports secondary analyses of data to explore behavioural and psychosocial aspects of sustained caloric restriction in humans. Grants are

worth up to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Role of gut microbiome in regulating reproduction and its impact on fertility status in women living with and without HIV (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research on the role of the gut microbiome in regulating metabolism and reproduction and its impact on fertility status. Grants are

worth up to USD 275,000 for up to two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Advancing research needed to develop a universal influenza vaccine (R21 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports the development of a universal influenza vaccine providing durable protection against multiple strains. Grants are each worth up to USD 275,000 over two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R03 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of alcohol or drugs singly or in combination. Grants

are each worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R21 clinical trial optional)

NIH: National Institute on Alcohol Abuse and Alcoholism

This supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of alcohol or

drugs singly or in combination. Grants are each worth up to USD 275,000 for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)

Novel approaches for relating genetic variation to function and disease (R21 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports the development of novel and generalisable approaches to study how genetic variants lead to differences in function, how such functional differences affect human health and disease processes or how this

knowledge can be used clinically. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 16 Oct 18

[Link to *Research Professional](#)



Innovation grants to nurture initial translational efforts (IGNITE) – neurotherapeutic agent characterisation and in vivo efficacy studies (R61/R33 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports pharmacodynamics, pharmacokinetics and in vivo efficacy studies to demonstrate that proposed therapeutic agents have sufficient biological activity to warrant further development to treat neurological

disorders. Funding is worth up to USD 750,000 per project for up to three years.

Closing date: 17 Oct 18

[Link to *Research Professional](#)

Innovation grants to nurture initial translational efforts (IGNITE) – assay development and therapeutic agent identification (R61/R33 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports research that develops in vitro or ex vivo assays and conducts iterative screening efforts to identify and characterise potential therapeutic agents for neurological disorders.

Grants are worth up to USD 750,000 each over three years.

Closing date: 17 Oct 18

[Link to *Research Professional](#)

Innovation grants to nurture initial translational efforts – development and validation of model systems and pharmacodynamic markers to facilitate the discovery of neurotherapeutics (R61/R33 clinical trials not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This encourages development and validation of animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder, or clinically feasible pharmacodynamic markers for

therapeutics designed to treat neurological disease. Awards are worth up to USD 750,000 for three years.

Closing date: 17 Oct 18

[Link to *Research Professional](#)

DEADLINE BROUGHT FORWARD: NCI clinical and translational exploratory or developmental studies (R21 clinical trial optional)

NIH: National Cancer Institute

*** The call schedule for this opportunity has been brought forward. The previous call schedule beginning 19 July 2018 has been brought forward to dates beginning 20 February 2018. All other call details remain unchanged. This call supports the development of

new exploratory research in cancer diagnosis and treatment. The combined budget may not exceed USD 275,000 for a period of up to two years. Closing date: 17 Oct 18

[Link to *Research Professional](#)



Joint DMS/NIGMS initiative to support research at the interface of the biological and mathematical sciences

National Science Foundation

This supports fundamental research to in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. Awards are each worth between USD 100,000 and

USD 400,000 per year for three to four years.

Closing date: 18 Oct 18

[Link to *Research Professional](#)

Innovative technologies to deliver genome editing machinery to disease-relevant cells and tissues (UG3/UH3 clinical trial not allowed)

NIH: National Center for Advancing Translational Sciences

This supports the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with the ultimate goal of accelerating the development of genome editing therapeutics to treat human disease. Grants are worth up to

USD 500,000 each per year for the UG3 phase, and up to USD 1 million each per year for the UH3 phase.

Closing date: 18 Oct 18

[Link to *Research Professional](#)

Development of cell and tissue platforms to detect adverse biological consequences of somatic cell genome editing (U01 clinical trial not allowed)

NIH: National Institutes of Health

This supports the development and validation of tissue- and cell-based platforms for assessing potential adverse biological consequences of somatic cell genome editing. Grants are

each worth up to USD 1.66 million over a maximum of four years.

Closing date: 18 Oct 18

[Link to *Research Professional](#)

Expanding the human genome editing repertoire (U01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports the development of novel and optimised alternatives to existing in vivo genome editing complexes. Grants are worth up to USD 250,000 each per

year for a maximum period of four years.

Closing date: 18 Oct 18

[Link to *Research Professional](#)



Innovative technologies to non-invasively monitor genome edited cells in vivo (UH2/UH3 clinical trial not allowed)

NIH: National Heart, Lung and Blood Institute

This supports the development of tools and technologies that will enable longitudinal monitoring and tracking of genome edited cells in humans to better assess the safety and efficacy of genome editing therapies. Grants are worth up

to USD 900,000 each for a maximum period of four years.

Closing date: 18 Oct 18

[Link to *Research Professional](#)

Joint DMS/NIGMS initiative to support research at the interface of the biological and mathematical sciences

National Science Foundation

This supports fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. The total budget is USD 5 million per year, funding 12 to 20 grants. Grants are expected to be range

from USD 100,000 to USD 400,000 per year for up to four years, depending on the project type.

Closing date: 18 Oct 18

[Link to *Research Professional](#)

Investigator-initiated genomic medicine research (R01 clinical trial optional)

NIH: National Human Genome Research Institute

This supports research that aims to advance the understanding and implementation of the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use. Grants are

worth up to USD 500,000 each in direct costs per year for up to four years.

Closing date: 19 Oct 18

[Link to *Research Professional](#)

Investigator-initiated genomic medicine research (R21 clinical trial optional)

NIH: National Human Genome Research Institute

This supports research that aims to advance the understanding and implementation of the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use. Grants are

worth up to USD 275,000 over a two-year period.

Closing date: 19 Oct 18

[Link to *Research Professional](#)



Investigator-initiated genomic medicine research (R01 clinical trial optional)

NIH: National Human Genome Research Institute

This supports the advancement of understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use. Grants are

worth up to USD 500,000 per year for up to four years.

Closing date: 19 Oct 18

[Link to *Research Professional](#)

Investigator-initiated genomic medicine research (R21 clinical trial optional)

NIH: National Human Genome Research Institute

This supports the advancement of understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use. Grants are

worth up to USD 275,000 for up to two years.

Closing date: 19 Oct 18

[Link to *Research Professional](#)

COMING SOON: Capacity building assistance for high-impact HIV prevention programme integration

Centers for Disease Control and Prevention (CDC)

*** This opportunity will be available soon. The next call is expected to open on 21 August 2018 and close on 20 October 2018. The following information is subject to change. This programme aims to strengthen the capacity of the HIV prevention

workforce to sustain high-impact HIV prevention interventions and strategies. The estimated total budget is USD 115m, to fund 20 awards. ***

Closing date: 20 Oct 18 (Forecast)

[Link to *Research Professional](#)

Translational neural devices programme (UG3/UH3 clinical trial required)

NIH: National Institute of Neurological Disorders and Stroke

This supports translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Application budgets are not

limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 22 Oct 18

[Link to *Research Professional](#)



Advancing extracellular RNA communication research – improved isolation and analysis of exRNA-carrier subclasses (UG3/UH3 clinical trial not allowed)

NIH: Office of the Director

This supports the development and evaluation of innovative separation tools, technologies and approaches that will enable the scientific community to rapidly and reproducibly sort complex biofluids into homogenous carrier populations. Awards are each worth up

to USD 300,000 per year for the UG3 phase, and up to USD 650,000 per year for the UH3 phase. The maximum project period is four years.

Closing date: 23 Oct 18

[Link to *Research Professional](#)

Advancing extracellular RNA communication research – towards single extracellular vesicle sorting, isolation and analysis of cargo (UG3/UH3 clinical trial not allowed)

NIH: Office of the Director

This supports the development of innovative technologies and reagents towards isolating single extracellular vesicles (EV) and the characterisation of the exRNA cargoes associated with specific EV subpopulations based on cell of origin and intended target cell. Grants

are each worth up to USD 300,000 per year for the UG3 phase and up to USD 650,000 per year for the UH3 phase, for up to four years.

Closing date: 23 Oct 18

[Link to *Research Professional](#)

Novel assays to address translational gaps in treatment development (UG3/UH3 clinical trial optional)

NIH: National Institute of Mental Health

This aims to identify neurophysiological measures as potential assays for treatment development research. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total duration of

the UG3 and UH3 period may not exceed four years.

Closing date: 24 Oct 18

[Link to *Research Professional](#)

Electronic nicotine delivery systems – basic mechanisms of health effects (R01 clinical trial not allowed)

NIH: Office of the Director

This supports basic research examining how electronic nicotine delivery systems aerosols affect normal and disease states relevant to human cells, tissues and organs. Application budgets

are not limited but should reflect the actual needs of the project. Funding is for up to five years.

Closing date: 24 Oct 18

[Link to *Research Professional](#)



Electronic nicotine delivery systems – population, clinical and applied prevention research (R01 clinical trial optional)

NIH: Office of the Director

This supports studies on electronic nicotine delivery systems that examine population-based, clinical and applied prevention of disease. Application budgets are not limited but should

reflect the actual needs of the project. Funding is for up to five years.

Closing date: 24 Oct 18

[Link to *Research Professional](#)

Electronic nicotine delivery systems – basic mechanisms of health effects (R21 clinical trial not allowed)

NIH: Office of the Director

This supports basic research that examines how electronic nicotine delivery systems aerosols affect normal and disease states relevant to human cells, tissues and organs. Budgets are

limited to USD 275,000 per project over a two-year period.

Closing date: 24 Oct 18

[Link to *Research Professional](#)

Electronic nicotine delivery systems – population, clinical and applied prevention research (R21 clinical trial optional)

NIH: Office of the Director

This supports studies on electronic nicotine deliver systems that examine population-based, clinical and applied prevention of disease, including aetiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behaviour among

different populations. Budgets are limited to USD 275,000 per project over a two-year period.

Closing date: 24 Oct 18

[Link to *Research Professional](#)

NCI small grants programme for cancer research (NCI omnibus R03 clinical trial optional)

NIH: National Cancer Institute

This supports small research projects on cancer that can be carried out in a short period of time with limited resources. A budget for direct costs of up to USD 50,000 per year may be

requested. The maximum project period is two years.

Closing date: 26 Oct 18

[Link to *Research Professional](#)



Neural regulation of cancer (R21)

NIH: National Cancer Institute

This announcement encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Application budgets are limited to

US\$275,000 over a two-year project period, with no more than US\$200,000 in direct costs allowed in any year.

Closing date: 27 Oct 18

[Link to *Research Professional](#)

Neural regulation of cancer (R01)

NIH: National Cancer Institute

This announcement encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Application budgets are not limited but

must reflect the needs of the project. The maximum funding period is five years.

Closing date: 27 Oct 18

[Link to *Research Professional](#)

BRAIN initiative – new concepts and early-stage research for large-scale recording and modulation in the nervous system (R21 clinical trial not allowed)

NIH: National Eye Institute

This seeks applications for unique and innovative technologies that are in early stages of development, including new and untested ideas that are in the initial stages of conceptualisation. The

combined budget for direct costs is USD 300,000 for up to two years.

Closing date: 29 Oct 18

[Link to *Research Professional](#)

Secondary analyses of existing datasets in heart, lung and blood diseases and sleep disorders (R21)

NIH: National Heart, Lung and Blood Institute

This aims to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioural research in areas

relevant to the NHLBI mission. Application budgets are worth up to USD 150,000 for a two year period. No more than USD 75,000 is allowed in any single year.

Closing date: 30 Oct 18

[Link to *Research Professional](#)



Research answers to the National Cancer Institute's provocative questions (R21 clinical trials optional)

NIH: National Cancer Institute

This supports research projects designed to solve specific problems and paradoxes in cancer research identified by the institute's provocative questions

initiative. Grants are worth up to USD 275,000 each over two years.

Closing date: 30 Oct 18

[Link to *Research Professional](#)

Research answers to the National Cancer Institute's provocative questions (R01 clinical trial optional)

NIH: National Cancer Institute

This supports research projects designed to solve specific problems and paradoxes in cancer research. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 30 Oct 18

[Link to *Research Professional](#)

Revision applications to R01 awards for research on the NCI's provocative questions (R01 clinical trial optional)

NIH: National Cancer Institute

This encourages research that directly addresses the National Cancer Institute's provocative questions, including research that helps validate, adopt and disseminate PQ research results that impact cancer research and

clinical care. Grants are worth up to USD 150,000 per year for up to two years.

Closing date: 30 Oct 18

[Link to *Research Professional](#)

Revision applications to U01 awards for research on the NCI's provocative questions (U01 clinical trial optional)

NIH: National Cancer Institute

This encourages research that directly addresses the National Cancer Institute's provocative questions, including research that helps validate, adopt and disseminate PQ research results that impact cancer research and

clinical care. Grants are worth up to USD 150,000 per year for up to two years.

Closing date: 30 Oct 18

[Link to *Research Professional](#)



NCCIH mind and body clinical trial cooperative agreement (U01): AIDS-related

NIH: National Center for Complementary and Integrative Health

This AIDS-related funding opportunity announcement supports investigator-initiated clinical trials of mind and body interventions to be used in future multi-site trials. Application budgets are not

limited but need to reflect the actual needs of the proposed project.

Closing date: 31 Oct 18

[Link to *Research Professional](#)





NOVEMBER

DEADLINE BROUGHT FORWARD: Tobacco use and HIV in low- and middle-income countries (R21 clinical trial optional)

NIH: National Cancer Institute

*** The closing date for this opportunity has been brought forward. The previous call schedule beginning 4 April 2019 has been brought forward to 4 April 2018. All other call details remain unchanged. This call supports exploratory or developmental research on tobacco use

and human immunodeficiency virus infection in LMICs. Applications budgets are limited to USD 275,000 for up to two years. ***

Closing date: 01 Nov 18

[Link to *Research Professional](#)

Tobacco use and HIV in low- and middle-income countries (R01 clinical trial optional)

NIH: National Cancer Institute

This supports research focused on tobacco use and human immunodeficiency virus infection in low- and middle-income countries. Application budgets are not limited but need to reflect the actual needs of the

proposed project. The maximum project period is five years.

Closing date: 01 Nov 18

[Link to *Research Professional](#)

Extracellular vesicles and substance use disorders (R01)

NIH: National Institute on Drug Abuse

This supports research that investigates the interplay between extracellular vesicles and substance use disorders. Application budgets must reflect the actual needs of the proposed project. A

project period of up to five years may be requested.

Closing date: 03 Nov 18

[Link to *Research Professional](#)

Extracellular vesicles and substance use disorders (R21)

NIH: National Institute on Drug Abuse

This supports research that investigates the interplay between extracellular vesicles and substance use disorders. The combined budget for direct costs for the two-year project period may not exceed USD 275,000. Applicants may

request a project period of up to two years.

Closing date: 03 Nov 18

[Link to *Research Professional](#)



Extracellular vesicles and substance use disorders (R21): AIDS-related

NIH: National Institute on Drug Abuse

This supports research that investigates the interplay between extracellular vesicles and substance use disorders. The combined budget for direct costs for the two year project period may not exceed USD 275,000. Applicants may

request a project period of up to two years.

Closing date: 03 Nov 18

[Link to *Research Professional](#)

Extracellular vesicles and substance use disorders (R01): AIDS-related

NIH: National Institute on Drug Abuse

This supports research that investigates the interplay between extracellular vesicles and substance use disorders. Application budgets must reflect the actual needs of the proposed project. A

project period of up to five years may be requested.

Closing date: 03 Nov 18

[Link to *Research Professional](#)

BRAIN initiative – targeted BRAIN circuits projects (R01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports research projects using innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behaviour. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 06 Nov 18

[Link to *Research Professional](#)

Development of novel non-steroidal contraceptive methods (R61/R33 clinical trial not allowed)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports and facilitates multidisciplinary research approaches for the development of novel non-steroidal contraceptive products for men and women that act prior to

fertilisation. Awards are worth up to USD 2 million each over five years.

Closing date: 06 Nov 18

[Link to *Research Professional](#)



Global brain and nervous system disorders research across the lifespan (R21 clinical trial optional)

NIH: Fogarty International Center

This encourages the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries. Application

budgets are limited to USD 125,000 per year in direct costs for up to two years.

Closing date: 07 Nov 18

[Link to *Research Professional](#)

Global brain and nervous system disorders research across the lifespan (R01 clinical trials optional)

NIH: National Eye Institute

This encourages innovative, collaborative research projects between US and low- and middle-income country scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs.

Application budgets are not limited but must reflect the needs to the proposed project over a period of up to five years.

Closing date: 07 Nov 18

[Link to *Research Professional](#)

DEADLINE BROUGHT FORWARD: Emerging global leader award (K43)

NIH: Fogarty International Center

*** The closing date for this opportunity has been brought forward. The previous deadline of 14 December 2017 has been brought forward to 7 November 2017. All other call details remain unchanged. This announcement provides research support and protected time to a research scientist from a low- or middle-income country with a junior

faculty position at an LMIC academic or research institution. The award provides a salary worth up to USD 75,000 per year and research development costs of up to USD 30,000 per year. ***

Closing date: 07 Nov 18

[Link to *Research Professional](#)

Translational research in paediatric and obstetric pharmacology and therapeutics (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports translational and clinical research as well as clinical trials that will advance knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in

women during pregnancy and lactation. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 07 Nov 18

[Link to *Research Professional](#)



Translational research in pediatric and obstetric pharmacology and therapeutics (R03)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation.

Application budgets are limited to USD 50,000 in direct costs per year. The maximum project period is two years.

Closing date: 07 Nov 18

[Link to *Research Professional](#)

Translational research in pediatric and obstetric pharmacology and therapeutics (R01 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports translational and clinical research as well as clinical trials that will advance knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Nov 18

[Link to *Research Professional](#)

Role of epitranscriptomics in development and disease (R01 clinical trial not allowed)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the participating institutes. Grants are

worth up to USD 499,999 each for a maximum period of five years.

Closing date: 07 Nov 18

[Link to *Research Professional](#)



Role of epitranscriptomics in development and disease (R21 clinical trial not allowed)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the institute. Grants are worth up to USD

275,000 each for a maximum period of two years.

Closing date: 07 Nov 18

[Link to *Research Professional](#)

Modular R01s in cancer control and population sciences (R01 clinical trial optional)

NIH: National Cancer Institute

This supports research in cancer control and population sciences. Grants are worth up to USD 250,000 each per year over a maximum period of five years.

Closing date: 07 Nov 18

[Link to *Research Professional](#)

Leveraging electronic medical records for psychiatric genetic research (R01 clinical trial not allowed)

NIH: National Institute of Mental Health

This supports projects that implement creative molecular epidemiological approaches that incorporate individual genetic information, including polygenic and specific genetic risk variants in existing large, population-based cohorts, registries or health systems to

conduct analyses that advance the understanding of the aetiology of severe mental disorders. Funding is for up to five years.

Closing date: 08 Nov 18

[Link to *Research Professional](#)

Leveraging electronic medical records for psychiatric genetic research (R01 (collab) clinical trial not allowed)

NIH: National Institute of Mental Health

This supports collaborative projects that implement creative molecular epidemiologic approaches to advance the understanding of the aetiology of

severe mental disorders. Funding is for up to five years.

Closing date: 08 Nov 18

[Link to *Research Professional](#)



EXTENDED DEADLINE: Early-stage preclinical validation of therapeutic leads for diseases of interest to the NIDDK (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

*** The closing date for this opportunity has been extended. The previous deadline of 5 February 2018 has been extended to 12 March 2018, in addition to all subsequent deadlines being extended. All other call details remain unchanged. This announcement aims to stimulate research and technology development to promote the early-stage preclinical validation of therapeutic leads such as small molecules or non-

viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. ***

Closing date: 12 Nov 18

[Link to *Research Professional](#)

BRAIN Initiative: tools to facilitate high-throughput microconnectivity analysis (R01)

NIH: National Institute of Mental Health

This seeks applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. The estimated total budget is USD 4 million and will fund approximately three to seven awards. Application budgets are not limited but

need to reflect the actual needs of the proposed project. The maximum project period is three years.

Closing date: 13 Nov 18

[Link to *Research Professional](#)

Exploring epigenomic or non-coding RNA regulation in the development, maintenance, or treatment of chronic pain (R61/R33 clinical trial optional)

NIH: National Institute on Drug Abuse

This supports the investigation of the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance or treatment of chronic pain. Grants are worth up to USD 300,000 per year for up to two

years for the R61 phase and up to USD 450,000 per year for up to three years for the R33 phase.

Closing date: 13 Nov 18

[Link to *Research Professional](#)



Chronic, non-communicable diseases and disorders across the lifespan – Fogarty international research training award (D43 clinical trial optional)

NIH: Fogarty International Center

This supports collaborative training programmes that will strengthen the capacity of a low- or middle income country institution to conduct research relevant to the sponsoring NIH institutes. Grants are worth up to USD

250,000 per year for a maximum period of five years.

Closing date: 13 Nov 18

[Link to *Research Professional](#)

Integrative omics to enhance therapeutics development for healthy ageing (UH2/UH3 clinical trial not allowed)

NIH: National Institute on Aging

This supports an integrative analysis of person-specific multiple omics measurements generated across multiple tissues to identify omics profiles associated with protection against multiple ageing conditions. One

award is available, worth up to USD 3.3 million in direct costs over five years.

Closing date: 14 Nov 18

[Link to *Research Professional](#)

Improving implementation of seek, test, treat and retain strategies among people who inject drugs in low- to middle-income countries (R01 clinical trial required)

NIH: National Institute on Drug Abuse

This supports developing and testing implementation approaches that scale-up evidence based interventions in low- to middle-income countries among people who inject drugs where they form an important component of the national HIV epidemic. Application

budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 15 Nov 18

[Link to *Research Professional](#)



Elucidating the functional roles of non-coding RNAs in viral infectious diseases (R21 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports the discovery of functional roles of non-coding RNAs in viral infectious diseases. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 15 Nov 18

[Link to *Research Professional](#)

Dissemination and implementation research in health (R21 clinical trial optional)

NIH: National Institute of Mental Health

This announcement encourages investigators to submit research grant applications that will develop strategies to implement evidence-based practices into public health, clinical practice, and community settings. Direct costs are

limited to USD 275,000 over a two-year period.

Closing date: 16 Nov 18

[Link to *Research Professional](#)

Studies at periviable gestation (R03 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. Application budgets are limited to a total of USD

100,000 in direct costs with up to USD 50,000 in direct costs per year. The maximum project period is two years.

Closing date: 16 Nov 18

[Link to *Research Professional](#)

Studies at periviable gestation (R21 clinical trial optional)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. Application budgets are limited to a total of USD

275,000 in direct costs over two years with up to USD 200,000 in direct costs per year.

Closing date: 16 Nov 18

[Link to *Research Professional](#)



Clarifying the relationship between delirium and Alzheimer's disease and related dementias (R21/R33 clinical trial optional)

NIH: National Institute on Aging

This aims to clarify the relationship between delirium and Alzheimer's disease and related dementias. Application budgets are worth up to USD 275,000 in direct costs over the two-year R21 phase, with no more than USD 200,000 allowed in any year. For

the three-year R33 phase, budgets are worth less than USD 500,000 in annual direct costs.

Closing date: 16 Nov 18

[Link to *Research Professional](#)

Investigator-initiated research in computational genomics and data science (R01 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high

value to the biomedical genomics community. Funding is for up to five years.

Closing date: 16 Nov 18

[Link to *Research Professional](#)

Investigator-initiated research in computational genomics and data science (R21 clinical trial not allowed)

NIH: National Human Genome Research Institute

This supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high

value to the biomedical genomics community. Direct costs are limited to USD 275,000 over a two-year project period.

Closing date: 16 Nov 18

[Link to *Research Professional](#)

Small-cell lung cancer consortium: therapeutic development and mechanisms of resistance (U01)

NIH: National Cancer Institute

This aims to establish research teams of the small cell lung cancer consortium to conduct research whose overall goals are to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations and to gain a better

understanding of the rapid development of clinical resistance to drug and radiation therapy. Application budgets are limited to US\$450,000 per year for up to five years.

Closing date: 17 Nov 18

[Link to *Research Professional](#)



Exploratory/developmental grants programme for basic cancer research in cancer health disparities (R21 clinical trial not allowed)

NIH: National Cancer Institute

This supports basic research studies into the biological or genetic causes and mechanisms of cancer health disparities. Grants are worth up to USD 275,000 each over two years.

Closing date: 19 Nov 18

[Link to *Research Professional](#)

Basic cancer research in cancer health disparities (R01 clinical trial not allowed)

NIH: National Cancer Institute

This supports basic, mechanistic research into the biological and genetic causes and mechanisms of cancer health disparities. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 19 Nov 18

[Link to *Research Professional](#)

Efficacy and mechanism evaluation programme – researcher-led workstream: 18/125

Department of Health and Social Care including NIHR

This supports studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-

term care. There are no fixed limits on the duration of projects or funding.

Closing date: 20 Nov 18

[Link to *Research Professional](#)

Early-stage development of informatics technologies for cancer research and management (U01)

NIH: National Cancer Institute

The purpose of this announcement is to invite co-operative agreement applications for the development of enabling informatics technologies. Direct costs may not exceed

US\$300,000 per year for the maximum project period of three years.

Closing date: 20 Nov 18

[Link to *Research Professional](#)



Innovative research in cancer nanotechnology (R01)

NIH: National Cancer Institute

These support the development of innovative research projects in cancer nanotechnology. Application budgets are limited to USD 450,000 in direct

costs per year. The maximum project period is five years.

Closing date: 20 Nov 18

[Link to *Research Professional](#)

Development of innovative informatics methods and algorithms for cancer research and management (R21)

NIH: National Cancer Institute

The purpose of this announcement is to invite exploratory and developmental applications for the development of innovative methods and algorithms in biomedical computing, informatics and data science addressing priority needs across the cancer research continuum.

Direct costs may not exceed US\$275,000 over the maximum project period of two years.

Closing date: 20 Nov 18

[Link to *Research Professional](#)

Computationally-defined behaviours in psychiatry (R21 clinical trial optional)

NIH: National Institute of Mental Health

This supports research that applies computational approaches to develop parametrically-detailed behavioural assays across mental-health-relevant domains of function. Grants are worth

up to USD 275,000 each for a maximum period of two years.

Closing date: 20 Nov 18

[Link to *Research Professional](#)

Efficacy and mechanism evaluation programme – commissioned calls for proposals: 18/126, 18/127, 18/128, 18/131

Department of Health and Social Care including NIHR

This supports studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-

term care. There are no fixed limits on the duration of projects or funding.

Closing date: 20 Nov 18

[Link to *Research Professional](#)



Research for patient benefit programme, round 37 – mental health themed call

Department of Health and Social Care including NIHR

This aims to generate research evidence in the priority field of mental health to improve, expand and strengthen the way that healthcare is delivered for patients, the public and the NHS. Grants

are worth up to £350,000 each over three years.

Closing date: 21 Nov 18

[Link to *Research Professional](#)

Image-guided drug delivery (R01 clinical trial optional)

NIH: National Cancer Institute

This supports innovative research projects that are focused on image-guided drug delivery, including real-time image guidance, monitoring, quantitative in vivo characterisations and validation of delivery and response. Application budgets are not limited, but

must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 22 Nov 18

[Link to *Research Professional](#)

DEADLINE BROUGHT FORWARD: NCI clinical and translational exploratory or developmental studies (R21 clinical trial optional): AIDS-related

NIH: National Cancer Institute

*** The call schedule for this opportunity has been brought forward. The previous deadlines beginning 19 July 2018 have been brought forward to dates beginning 22 March 2018. All other call details remain unchanged. This AIDS-related call supports the development of new exploratory

research in cancer diagnosis and treatment. The combined budget may not exceed USD 275,000 for a period of up to two years. ***

Closing date: 22 Nov 18

[Link to *Research Professional](#)

Emerging questions in cancer systems biology (U01)

NIH: National Cancer Institute

This announcement seeks co-operative agreements applications for research projects that utilise systems biology approaches to address emerging questions in cancer initiation, progression, and treatment. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is 5 years.

Closing date: 23 Nov 18

[Link to *Research Professional](#)



Collaborative research in computational neuroscience programme

National Science Foundation

This supports collaborative activities that will advance the understanding of nervous system structure and function, mechanisms underlying nervous system disorders and computational strategies used by the nervous system. International components of

collaborative projects may be funded in parallel by the participating agencies. NIH awards are worth up to USD 250,000 per year in direct costs.

Closing date: 27 Nov 18

[Link to *Research Professional](#)

BRAIN initiative – new technologies and novel approaches for large-scale recording and modulation in the nervous system (U01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity to enable transformative understanding of dynamic signalling in

the nervous system. A total of USD 10 million per year is shared between 15 to 20 awards.

Closing date: 27 Nov 18

[Link to *Research Professional](#)

BRAIN initiative – optimisation of transformative technologies for large scale recording and modulation in the nervous system (U01 clinical trials not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports the optimisation of existing and emerging technologies and approaches that have potential to address major challenges associated with recording and manipulating neural activity in any region and throughout

the entire depth of the brain. Funding is for three years.

Closing date: 27 Nov 18

[Link to *Research Professional](#)

BRAIN initiative – new technologies and novel approaches for large-scale recording and modulation in the nervous system (R01 clinical trial not allowed)

NIH: National Institute of Neurological Disorders and Stroke

This supports proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity to enable transformative understanding of dynamic signalling in

the nervous system. The total budget is USD 10 million per year to fund 15 to 20 awards.

Closing date: 27 Nov 18

[Link to *Research Professional](#)



Drug transport across the blood-testis and blood-epididymal barriers (R61/R33 clinical trial not allowed)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports in vivo research to elucidate the chemical features of non-native molecules that facilitate passage across the blood-testis or blood-epididymal barriers. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 27 Nov 18

[Link to *Research Professional](#)

Discovery of biomarkers, biomarker signatures and endpoints for pain (R61/R33 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke

This supports the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through phase II clinical trials. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 27 Nov 18

[Link to *Research Professional](#)

Programme grants for applied research, competition 28 – mental health themed call

Department of Health and Social Care including NIHR

This supports research teams in England to improve health outcomes in the priority area of mental health. Awards are usually worth up to £2.5 million each over six years.

Closing date: 28 Nov 18

[Link to *Research Professional](#)

Programme development grants – competition 23

Department of Health and Social Care including NIHR

These aim to position and equip research teams in submitting a full programme grants for applied research in the future. Grants are worth up to £100,000 each over up to 18 months.

Closing date: 28 Nov 18

[Link to *Research Professional](#)



Cancer tissue engineering collaborative: enabling biomimetic tissue-engineered technologies for cancer research (U01)

NIH: National Cancer Institute

This announcement supports the development and characterisation of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Application budgets are limited to US\$400,000 in direct costs

per year for a maximum period of five years.

Closing date: 30 Nov 18

[Link to *Research Professional](#)



Sustained release innovation for HIV (R61/R33 clinical trial optional)

NIH: National Institute of Allergy and Infectious Diseases

This supports the development of new and innovative sustained or extended release drugs and drug delivery systems that can achieve extended durations of HIV prevention in at-risk individuals. Grants are worth up to USD 800,000 each per year for up to three years for

the R61 phase and up to USD 1.6 million per year for up to two years for the R33 phase.

Closing date: 30 Nov 18

[Link to *Research Professional](#)





DECEMBER

Expanding extramural research opportunities at the NIH clinical centre (U01 clinical trial optional)

NIH: National Institute of Allergy and Infectious Diseases

This supports extramural investigator-initiated clinical research in partnership with the NIH clinical centre in Bethesda, MD. Up to three awards are available,

worth up to USD 400,000 each per year over a maximum period of five years.

Closing date: 03 Dec 18

[Link to *Research Professional](#)

Telomeres as sentinels of environmental exposures, psychosocial stress, and disease susceptibility – a methods comparison study (U01 clinical trial optional)

NIH: National Institute on Aging

This supports the development of best-practice guidelines for population-based telomere length research. Three to four awards, worth up to USD

200,000 each per year for a maximum period of three years, are available.

Closing date: 03 Dec 18

[Link to *Research Professional](#)

Novel approaches to safe, non-invasive, real time assessment of human placenta development and function across pregnancy (R01 clinical trial not allowed)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports the development of safe, real-time, non-invasive, in vivo methods to assess the development and function of the human placenta across

pregnancy. Funding is for up to five years.

Closing date: 04 Dec 18

[Link to *Research Professional](#)

Novel approaches to safe, non-invasive, real time assessment of human placenta development and function across pregnancy (R21 clinical trial not allowed)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports that research that uses novel approaches for the development of safe, real-time, non-invasive, or minimally invasive, in vivo methods to

assess the development and function of the human placenta across pregnancy. Grants are worth up to USD 275,000 each for up to two years.



Closing date: 04 Dec 18

[Link to *Research Professional](#)

Halting tuberculosis transmission in HIV-endemic and other high-transmission settings (R01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports multidisciplinary studies of transmitter-recipient cluster chains members to characterise host-pathogen-microenvironment interactions, and the effect of HIV co-infection that affect mycobacterium tuberculosis transmission in high-

burden settings. Funding is for five years. The total budget for the fiscal year 2019 is USD 5.8 million, covering four to six awards.

Closing date: 05 Dec 18

[Link to *Research Professional](#)

HIV drug resistance – genotype-phenotype-outcome correlations (R01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports studies that evaluate HIV drug resistance and its relationship to treatment success. Grants are worth up to USD 500,000 each per year over a maximum period of five years.

Closing date: 05 Dec 18

[Link to *Research Professional](#)

Systems developmental biology for understanding embryonic development and the ontogeny of structural birth defects (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

The purpose of these R01 grants is to promote systems developmental biology. Systems developmental biology is defined as research focused on understanding how biological components work together to produce the complex biological phenomena

encompassing embryonic development. Budgets are not limited but must reflect the actual needs of the project.

Closing date: 06 Dec 18

[Link to *Research Professional](#)

Clinical, behavioural and physiological research testing current and novel closed loop systems (R01 clinical trial required)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports clinical studies to test a reliable, wearable or implantable, portable, and easy to operate system linking continuous glucose monitoring and pancreatic hormone delivery in a

close loop system. Application budgets are limited to USD 500,000 in direct costs per year for up to four years.

Closing date: 06 Dec 18

[Link to *Research Professional](#)



Mechanisms underlying the contribution of type 1 diabetes disease-associated variants (R01 clinical trial not allowed)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports projects to determine the mechanisms underlying the contribution of these risk-associated genes and their variants for type 1 diabetes. Grants are worth up to USD

600,000 each per year for a period of four years.

Closing date: 06 Dec 18

[Link to *Research Professional](#)

Impact of the use of glucose monitoring and control technologies on health outcomes and quality of life in older adults with type 1 diabetes (R01 clinical trial required)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports clinical studies of the use of current and emerging technologies for monitoring of blood glucose and insulin administration in adults aged 65 years and older. Application budgets are

limited to USD 500,000 direct costs per year for up to four years.

Closing date: 06 Dec 18

[Link to *Research Professional](#)

Detection of HIV for self-testing (R61/R33)

NIH: National Institute of Allergy and Infectious Diseases

This supports bi-phasic developmental, discovery-driven, or hypothesis-driven research focused on innovative strategies to detect HIV either within the first two weeks of infection or to monitor viral rebound after stopping or developing resistance to antiretroviral

therapy. Application budgets are limited to USD 300,000 in direct costs per year in the R61 phase and USD 500,000 in direct costs per year in the R33 phase.

Closing date: 06 Dec 18

[Link to *Research Professional](#)

Immune system engineering for targeted tolerance in type 1 diabetes (R01 clinical trial not allowed)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports projects that seek to discover ways to change the course of type 1 diabetes by directly establishing tolerance. Application budgets are

limited to USD 300,000 in direct costs per year for up to five years.

Closing date: 06 Dec 18

[Link to *Research Professional](#)



Characterisation and discovery of novel autoantigens and epitopes in type 1 diabetes (R01 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports original research aimed at the characterisation and discovery of neoantigens and neopeptides in type 1 diabetes. Grants are worth between

USD 250,000 and USD 500,000 each per year for up to four years.

Closing date: 06 Dec 18

[Link to *Research Professional](#)

Understanding skeletal effects of type 1 diabetes (R01 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports studies to understand the effects of type 1 diabetes on bone mass and quality or fracture risk. Grants are worth up to USD 400,000 each per year over five years.

Closing date: 06 Dec 18

[Link to *Research Professional](#)

Understanding skeletal effects of type 1 diabetes (R01 clinical trial optional)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports studies to understand the effects of type 1 diabetes on bone mass and quality or fracture risk.

Applications may request up to USD 400,000 per year for up to five years.

Closing date: 06 Dec 18

[Link to *Research Professional](#)

Investigator initiated extended clinical trial (R01 clinical trial required)

NIH: National Institute of Allergy and Infectious Diseases

This supports clinical trials of any phase that require an extended project period of six or seven years and are hypothesis-driven and related to the research mission of one of the participating institutes. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is seven years.

Closing date: 07 Dec 18

[Link to *Research Professional](#)



Investigator initiated extended clinical trial (R01 clinical trial required): AIDS-related

NIH: National Institute of Allergy and Infectious Diseases

This AIDS-related call supports trials of any phase that require an extended project period of six or seven years and are hypothesis-driven and related to the research mission of one of the participating institutes. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is seven years.

Closing date: 07 Dec 18

[Link to *Research Professional](#)

Imaging and biomarkers for early detection of aggressive cancer (U01)

NIH: National Cancer Institute

This announcement seeks collaborative research project applications to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk and cancer diagnosis aimed at integrating multi-modality imaging strategies and multiplexed biomarker methodologies

into a singular complementary approach. Application budgets are not limited, but must reflect actual needs of the project. The maximum project period is five years.

Closing date: 11 Dec 18

[Link to *Research Professional](#)

BRAIN initiative – proof of concept development of early stage next generation human brain imaging (R01 clinical trials not allowed)

NIH: National Institute of Biomedical Imaging and Bioengineering

This supports early stage development of entirely new and novel non-invasive human brain imaging technologies and methods that lead to transformative advances in the understanding of the human brain. Application budgets are

limited to USD 300,000 in direct costs in any project year. The maximum project period is two years.

Closing date: 11 Dec 18

[Link to *Research Professional](#)

BRAIN initiative – development of next generation human brain imaging tools and technologies (U01 clinical trials not allowed)

NIH: National Institute of Biomedical Imaging and Bioengineering

This supports full development of entirely new or next generation non-invasive human brain imaging tools and methods that lead to transformative advances in the understanding of the human brain. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 11 Dec 18

[Link to *Research Professional](#)



Modelling and simulation to optimise HIV prevention research (R01 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases

This supports the development and validation of modelling and simulation methods and related tools to examine HIV transmission dynamics, make epidemic projections and estimate the impact of HIV treatment and

prevention. Two to four awards are available, each worth up to USD 400,000 per year for up to four years.

Closing date: 13 Dec 18

[Link to *Research Professional](#)



Cutting-edge basic research awards (R21 clinical trial optional)

NIH: National Institute on Drug Abuse

This aims to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention or treatment of substance abuse disorders. Direct costs are limited to USD 275,000 over a two-year project

period, with no more than USD 150,000 in any single year.

Closing date: 20 Dec 18

[Link to *Research Professional](#)

